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A B S T R A C T
Background
There are three approaches to hysterectomy for benign disease - abdominal hysterectomy (AH), vaginal hysterectomy (VH) and la-
paroscopic hysterectomy (LH). Laparoscopic hysterectomy has three further subdivisions - laparoscopic assisted vaginal hysterectomy
(LAVH) where a vaginal hysterectomy is assisted by laparoscopic procedures that do not include uterine artery ligation, laparoscopic
hysterectomy (which we will abbreviate to LH(a)) where the laparoscopic procedures include uterine artery ligation, and total laparo-
scopic hysterectomy (TLH) where there is no vaginal component and the vaginal vault is sutured laparoscopically.
Objectives
To assess the most appropriate surgical approach to hysterectomy.
Search strategy
We searched the Cochrane Menstrual Disorders & Subfertility Group’s Specialised Register of controlled trials (searched 23 March
2004), CENTRAL (The Cochrane Library Issue 1, 2004), MEDLINE (1966 to Mar 2004), EMBASE (1985 to Mar 2004), Biological
Abstracts (1968 to Mar 2004), the National Research Register and relevant citation lists.
Selection criteria
Only randomised trials comparing one surgical approach to hysterectomy with another were included.
Data collection and analysis
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Twenty-seven trials that included 3643 participants were included. Independent selection of trials and data extraction were employed
following Cochrane guidelines.
Main results
The benefits of VH versus AH were shorter duration of hospital stay (WMD 1.0 day, 95%CI 0.7 to 1.2 days), speedier return to
normal activities (WMD 9.5 days, 95%CI 6.4 to 12.6 days), fewer unspecified infections or febrile episodes (OR 0.42, 95%CI 0.21
to 0.83). The benefits of LH versus AH were lower intraoperative bloodloss (WMD 45.3 mls, 95%CI 17.9 to 72.7 mls) and a smaller
drop in haemoglobin level (WMD 0.55g/L, 95%CI 0.28 to 0.82g/L), shorter duration of hospital stay (WMD 2.0 days, 95%CI
1.9 to 2.2 days), speedier return to normal activities (WMD 13.6 days, 95%CI 11.8 to 15.4 days), fewer wound or abdominal wall
infections (OR 0.32, 95%CI 0.12 to 0.85), fewer unspecified infections or febrile episodes (OR 0.65, 95%CI 0.49 to 0.87), at the
cost of longer operating time (WMD 10.6 minutes, 95%CI 7.4 to 13.8 minutes) and more urinary tract (bladder or ureter) injuries
(OR 2.61, 95%CI 1.22 to 5.60). There was no evidence of benefits of LH versus VH and the operating time was increased (WMD
41.5 minutes, 95%CI 33.7 to 49.4 minutes). There was no evidence of benefits of LH(a) versus LAVH and the operating time was
increased for LH(a) (WMD 25.3 minutes, 95%CI 10.0 to 40.6 minutes). There was statistical heterogeneity in many of the outcome
measures when randomised trials were pooled for meta-analysis. No other statistically significant differences were found. However, for
some important outcomes, the analyses were underpowered to detect important differences, or they were simply not reported in trials.
Data were notably absent for many important long-term outcome measures.
Authors’ conclusions
Significantly improved outcomes suggest VH should be performed in preference to AH where possible. Where VH is not possible, LH
may avoid the need for AH, however the length of the surgery increases as the extent of the surgery performed laparoscopically increases,
particularly when the uterine arteries are divided laparoscopically and laparoscopic approaches require greater surgical expertise. The
surgical approach to hysterectomy should be decided by a woman in discussion with her surgeon in light of the relative benefits and
hazards. Further research is required with full reporting of all relevant outcomes, particularly important long-term outcomes, in large
RCTs, to minimise the possibility of reporting bias. Further research is also required to define the role of the newer approaches to
hysterectomy such as TLH.
P L A I N L A N G U A G E S U M M A R Y
Surgical approach to hysterectomy for benign gynaecological disease
Vaginal hysterectomy should be performed in preference to abdominal hysterectomy where possible. Abdominal hysterectomy involves
removal of the uterus through a large incision on the lower abdomen; vaginal hysterectomy involves removal of the uterus via the
vagina, with no abdominal incision; laparoscopic hysterectomy involves ’keyhole surgery’ small incisions on the abdomen and the
uterus is removed with surgery undertaken with the aid of a surgical telescope called a laparoscope inserted through the umbilicus
(belly button), often in conjunction with vaginal surgery. Laparoscopic hysterectomy may be further subdivided depending on the
extent of the surgery performed laparoscopically compared to that performed vaginally. This review found that vaginal hysterectomy
meant a shorter stay in hospital, quicker return to normal activities and fewer infections and episodes of raised temperature after surgery
compared to abdominal hysterectomy. Laparoscopic hysterectomy meant were less blood loss and a smaller drop in blood count, a
shorter stay in hospital, quicker return to normal activities, fewer wound infections and episodes of raised temperature after surgery
compared to abdominal hysterectomy, but laparoscopic hysterectomies are longer operations and have a greater risk of damaging the
bladder or ureter (the tube leading to the bladder from the kidney). No benefits of laparoscopic versus vaginal hysterectomy were
found and laparoscopic hysterectomies are longer operations. The authors concluded that vaginal hysterectomy should be performed in
preference to abdominal hysterectomy where possible; where vaginal hysterectomy is not possible, a laparoscopic approach may avoid
the need for an abdominal hysterectomy. More research is needed.
B A C K G R O U N D
Hysterectomy is the surgical removal of the uterus. The first re-
ported elective hysterectomy was performed through a vaginal ap-
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proach by Conrad Langenbeck in 1813. The first elective abdomi-
nal hysterectomy, a sub-total operation (where the cervix was con-
served), was performed by Charles Clay of Manchester in 1863 (
Sutton 1997). These approaches remained the only two options
until the latter part of the 20th century. The first laparoscopic-
assisted vaginal hysterectomy was performed by Harry Reich in
1989 (Reich 1989). He also reported the first total laparoscopic
hysterectomy in 1993. The approaches to hysterectomy may be
broadly categorised into three: abdominal hysterectomy (AH);
vaginal hysterectomy (VH); laparoscopic hysterectomy where at
least some of the operation is conducted laparoscopically (which
we will abbreviate to LH) (Garry 1994).
The abdominal approach (AH) has traditionally been the surgi-
cal approach for gynaecological malignancy, when other pelvic
pathology is present such as endometriosis or adhesions, and in
the context of an enlarged uterus. It remains the ’fallback option’
if the uterus cannot be removed by another approach.
The vaginal approach (VH) was originally used only for prolapse,
but has become more widely used for menstrual abnormalities
such as dysfunctional uterine bleeding (DUB) when the uterus is
fairly normal size. Compared to AH, VHwas (and still is) regarded
as less invasive and seemed to have the advantages of fewer blood
transfusions, less febrile morbidity (fever) and less risk of injury to
the ureter, but the disadvantages of more bleeding complications
and greater risk of bladder injury (Harris 1996).
The term ’laparoscopic hysterectomy’ usually refers to a hysterec-
tomy where at least part of the operation is undertaken laparo-
scopically (Garry 1994) and these approaches require greater sur-
gical expertise. The proportion of hysterectomies performed by
LH has gradually increased and, although the surgery tends to
take longer, its proponents have argued that the main advantages
are the possibility to diagnose and treat other pelvic diseases such
as endometriosis, to carry out adnexal surgery including the re-
moval of the ovaries, the ability to secure thorough intraperitoneal
haemostasis (direct laparoscopic vision enables careful sealing of
bleeding vessels at the end of the procedure) and a more rapid
recovery time from surgery compared to AH (Garry 1998). More
recently, three sub-categorisations of LH have been described (
Reich 2003) as follows.
(i) Laparoscopic assisted vaginal hysterectomy (LAVH) is where
part of the hysterectomy is performed by laparoscopic surgery and
part vaginally, but the laparoscopic component of the operation
does not involve division of the uterine vessels.
(ii) Laparoscopic hysterectomy (which we will abbreviate to
LH(a)) is where the uterine vessels are ligated laparoscopically but
part of the operation is performed vaginally.
(iii) Total laparoscopic hysterectomy (TLH) is where the entire
operation (including suturing of the vaginal vault) is performed
laparoscopically and there is no vaginal component. This opera-
tion requires the highest degree of surgical skill and currently only
a very small proportion of gynaecologists are able to perform this
type of surgery. It has been unclear whether TLH offers any benefit
over other forms of hysterectomy.
A total hysterectomy is the removal of the entire uterus including
the cervix. When the cervix is not removed, this is known as a sub-
total or supra-cervical hysterectomy. Sub-total hysterectomies are
most easily performed abdominally or laparoscopically, although
it is possible to conserve the cervix in a VH or LAVH.
In common with the overall hysterectomy rate, the proportion of
hysterectomies currently being performed by each of the above ap-
proaches varies markedly across countries, within the same coun-
try and even between individual surgeonsworking within the same
unit. Women’s expectations and individual surgeons’ training and
experience are factors underlying this. Even though VH has been
widely considered to be the operation of choice for dysfunctional
uterine bleeding (DUB), the VALUE Study showed that 74% of
the hysterectomies performed in 1995 for this indication in the
UK were AHs (Hall 1998). The surgical approach taken at hys-
terectomy continues to depend upon the experience and biases of
the surgeon (Johns 1995). It was interesting to note in 1998 that
there was not a single randomised controlled trial (RCT) compar-
ing AH versus VH (Garry 1998). The introduction of the newer
approaches to hysterectomy (LAVH, LH(a) and TLH) has stim-
ulated a much greater interest in the proper scientific evaluation
of all forms of hysterectomy.
Apart from the surgical approach to hysterectomy, other aspects
of the surgical technique may have an effect on the outcome of
surgery. Examples of this include total versus subtotal (where the
cervix is not removed) hysterectomy; Doderlein VH or LAVH
versus standard VH or LAVH; techniques to support the vaginal
vault; bilateral elective oophorectomy versus ovarian conservation;
other strategies, used mainly by those conducting laparoscopic
surgery with the aim of reducing the likelihood of complications,
including the use of vaginal delineators, rectal probes and illumi-
nated ureteric stents. These other aspects will not be within the
scope of this review (other than for assessing trial quality) which
will focus simply on benefits and harms of the different surgical
approaches.
O B J E C T I V E S
The aim of this review was to assess the most beneficial and least
harmful surgical approach to hysterectomy, when considering ab-
dominal hysterectomy (AH), vaginal hysterectomy (VH), laparo-
scopic hysterectomy (LH) for women with benign gynaecological
conditions.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) where one surgical approach
to hysterectomy is compared with another.
Types of participants
Women undergoing hysterectomy for benign disease (including
uterine fibroids).
Exclusions - women with gynaecological cancer. Where trials in-
cluded women with benign and women with malignant disease,
authors would have been requested for a breakdown in order to
include only women with benign disease and trials would have
been be excluded if this information was not forthcoming; in the
event there were no such trials.
Types of interventions
Surgical approach to removal of the uterus - where at least one
approach is compared with another from, for example, AH, VH
and LH. The distinction between the sub-categories of LH was
made on whether ligation of the uterine vessels was undertaken
laparoscopically and whether suturing of the vaginal vault was
undertaken vaginally (see Table 1). Thus LH was further sub-di-
vided in the analysis into LAVH (where the laparoscopic compo-
nent did not involve ligation of the uterine vessels), LH(a) (where
the uterine vessels were ligated laparoscopically, but there was still
some vaginal component), TLH (where the entire hysterectomy
was completed laparoscopically with no vaginal component) and
non-categorisable LH (where there was insufficient information
or the types of LH were too heterogeneous to otherwise sub-cat-
egorise). There are two other classifications of LH (Richardson
1995; Nezhat 1995) and these are summarised in Table 2 and
Table 3.
Table 1. Sub-categorisation of laparoscopic hysterectomy
Type of LH LH versus AH RCTs LH versus VH RCTs
LAVH Ferrari 2000 Ottosen 2000
Kunz 1996
Marana 1999
Ottosen 2000
Raju 1994b
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Table 1. Sub-categorisation of laparoscopic hysterectomy (Continued)
Tsai 2003
LH(a) Ellstrom 1998 Darai 2001
Falcone 1999 Hwang 2002
Harkki-Siren 2000 Soriano 2001
Hwang 2000 Summitt 1992
Langebrekke 1998
Olsson 1996
Schutz 2002
Seracchiolo 2002
Summitt 1998
Yuen 1998
TLH Perino 1999 Ribiero 2003
Ribiero 2003
Non-categorisable LH Garry 2004 Garry 2004
Lumsden 2000 Richardson 1998
Table 2. Staging of laparoscopic hysterectomy - Richardson 1995
Stage Laparoscopic content
0 Laparoscopy done but no laparoscopic procedure before vaginal hysterectomy
1 Procedure includes laparoscopic adhesiolysis and/or excision of endometriosis
2 Either or both adnexae freed laparoscopically
3 Bladder dissected from the uterus laparoscopically
4 Uterine artery transected laparoscopically
5 Anterior and/or posterior colpotomy or entire uterus freed laparoscopically
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Table 3. Steps of laparoscopic hysterectomy - Nezhat 1995
Step Laparoscopic content
1 Severing the round ligaments and dissection of the upper portion of the broad ligament
2 Severing the tubo-uterine junction and the utero-ovarian ligament if the adnexa are to be preserved, or severing the infundibu-
lopelvic ligaments
3 Severing the uterine vessels
4 Preparation of the bladder flap
5 Severing the cardinal uterosacral ligaments complex
6 Performing anterior and posterior culdotomy and separation of the cervix
7 Closure of the vaginal cuff
(The reason for choosing to sub-categorise is that many surgeons
carrying out LH operations are practitioners of one or the other
operation and require information about their perspective on the
surgery. Clinicians often do not regard the three options for the
approach to LH as easily interchangeable.)
Sub-total versus total hysterectomy is the scope of another
Cochrane review and trials making this comparison will be ex-
cluded from this review. Trials evaluating different surgical ap-
proaches to hysterectomy will also be excluded. However, if a mi-
nority of the trial participants had a sub-total hysterectomy, but
the comparison was made between any of the three approaches
outlined above, the trial would be included.
Types of outcome measures
Not all clinical outcome data are of equal importance when as-
sessing the worth of a technique. It is not possible to define some
of these outcomes as ’primary’ without unduly imposing reviewer
bias on the review, since the effect of certain approaches for many
of the outcome measures is predictable. For example, LH has the
reputation of being associated with a longer operating time (a
detrimental effect of this approach), but a shorter hospital stay (a
beneficial effect).
The outcome measures were therefore considered as follows:
(1) Operating time
(2) Immediate complications of surgery:
(a) Urinary tract (bladder or ureter) injury
(b) Bladder injury
(c) Ureter injury
(d) Bowel injury
(e) Vascular injury
(f ) Bleeding
(g) Unintended laparotomy for approaches not involving routine
laparotomy
(3) Short-term outcomes:
(a) Pain
(b) Sequelae of bleeding:
(i) Haemoglobin/haematocrit drop
(ii) Transfusion
(iii) Pelvic haematoma
(c) Infection:
(i) Vaginal cuff
(ii) Abdominal wall or wound
(iii) Urinary tract infection (UTI)
(iv) Febrile episodes or unspecified infection
(d) Thrombo-embolism
(e) Perioperative mortality
(4) Recovery from surgery:
(a) Length of hospital stay
(b) Return to normal activities
(5) Long-term outcomes:
(a) Fistula
(b) Pelvi-abdominal pain
(c) Urinary dysfunction
(d) Bowel dysfunction
(e) Pelvic floor condition (prolapse)
(f ) Sexual dysfunction
(g) Satisfaction/quality of life
(6) Data on the cost of treatment were sought but it was intended
to describe these data qualitatively and not to include in the meta-
analysis, since ’cost’ could be defineddifferently in different studies
depending upon whether they incorporate the cost of sequelae.
Different health-care systems could produce markedly different
results.
Search methods for identification of studies
(1) We searched the Cochrane Menstrual Disorders and Subfertil-
ityGroup (MDSG)TrialsRegister (23March 2004), theCochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane
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Library Issue 1, 2004),MEDLINE (January 1966 toMarch 2004),
EMBASE (January 1985 toMarch 2004), andBiological Abstracts
(1969 to March 2004).
MEDLINE was searched using the following strategy:
1 randomised controlled trial.pt.
2 controlled clinical trial.pt.
3 Randomized controlled trials/
4 random allocation/
5 double-blind method/
6 single-blind method/
7 or/1-6
8 clinical trial.pt.
9 exp clinical trials/
10 (clin$ adj25 trial$).ti,ab,sh.
11 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or
mask$)).ti,ab,sh.
12 placebos/
13 placebo$.ti,ab,sh.
14 random$.ti,ab,sh.
15 Research design/
16 or/8-15
17 animal/ not (human/ and animal/)
18 7 or 16
19 18 not 17
20 exp HYSTERECTOMY/
21 Hysterectom$.tw.
22 20 or 21
23 abdom$.tw.
24 vaginal$.tw.
25 (Lap$ adj Assist$).tw.
26 (Lap$ adj Vaginal$).tw.
27 LAVH.tw.
28 LH.tw.
29 or/23-28
30 22 and 29
31 route$.tw.
32 technique$.tw.
33 approach$.tw.
34 or/31-33
35 30 and 34
36 19 and 35
EMBASE was searched using the following strategy:
1 Controlled study/ or randomized controlled trial/
2 double blind procedure/
3 single blind procedure/
4 crossover procedure/
5 drug comparison/
6 placebo/
7 random$.ti,ab,hw,tn,mf.
8 latin square.ti,ab,hw,tn,mf.
9 crossover.ti,ab,hw,tn,mf.
10 cross-over.ti,ab,hw,tn,mf.
11 placebo$.ti,ab,hw,tn,mf.
12 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or
mask$)).ti,ab,hw,tn,mf.
13 (comparative adj5 trial$).ti,ab,hw,tn,mf.
14 (clinical adj5 trial$).ti,ab,hw,tn,mf.
15 or/1-14
16 nonhuman/
17 animal/ not (human/ and animal/)
18 or/16-17
19 15 not 18
20 exp HYSTERECTOMY/
21 hysterectom$.tw.
22 20 or 21
23 abdom$.tw.
24 vaginal$.tw.
25 (Lap$ adj Assist$).tw.
26 (Lap$ adj Vaginal$).tw.
27 LAVH.tw.
28 LH.tw.
29 or/23-28
30 exp Surgical Technique/
31 route$.tw.
32 technique$.tw.
33 approach$.tw.
34 or/30-33
35 22 and 29
36 34 and 35
37 19 and 36
The Cochrane Central Register of Controlled Trials (CENTRAL)
was searched in all fields using the following key words:
1. Hysterectomy
2. Abdominal
3. Vaginal
4. Laparoscopic assisted
5. Laparo-vaginal
6. Laparoscopic
7. 1 and 2 or 3 or 4 or 5 or 6
(2) The National Research Register (NRR), a register of ongoing
and recently completed research projects funded by, or of interest
to, theUnitedKingdom’sNationalHealth Service, aswell as entries
from the Medical Research Council’s Clinical Trials Register, and
details on reviews in progress collected by the NHS Centre for
Reviews and Dissemination, were searched for any trials with the
following keywords:
1. Hysterectomy
2. Abdominal
3. Vaginal
4. Laparoscopic assisted
5. Laparo-vaginal
6. Laparoscopic
7. 1 and 2 or 3 or 4 or 5 or 6
(3) The Clinical Trials register, a registry of federally and privately
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funded US clinical trials was also searched for the same keywords.
(4) The citation lists of relevant publications, review articles,
abstracts of scientific meetings and included studies were also
searched.
Data collection and analysis
Selection of trials
The selection of trials for inclusion in the review was performed by
at least two of four reviewers (ET, EC, AL andNJ) after employing
the search strategy described previously. Differences of opinion
were resolved by consensus after consultation with one or two
other reviewers.
Trials were excluded from the review if they made comparisons
other than those specified above and these were detailed in the
table of characteristics of excluded trials.
Quality assessment
Included studies were assessed independently by two reviewers
(ET and AL) for the following quality criteria and methodological
details. This information is presented in a table describing the
included studies and provides a context for assessing the reliability
of results. All RCTs were included in the review, but sensitivity
analyses were planned to assess the stability of results with respect
to where trials compared a surgical approach performed by one
surgeon with another surgical approach performed by a second
surgeon (which cannot tease out the ’surgeon effect’ from the effect
of the surgical approach).
(A) Trial characteristics
(a) Method of randomisation, in order of preference, as follows:
(i) third party randomisation, for example by pharmacy, computer
or telephone
(ii) true randomisation by carer, for example by opaque numbered
envelope or register
(iii) not stated
(b) Study design:
(i) blinding
(ii) duration of follow-up
(iii) type of follow-up
(c) Size of study:
(i) number of women recruited
(ii) number of women randomised
(iii) number of women excluded
(iv) number of women withdrawn and lost to follow-up
(v) number of women analysed
(d) Study setting
(i) Single-centre or multicentre
(ii) Location
(iii) Timing and duration
(iv) Source of funding stated or not
(e) Analyses
(i) Whether a power calculation was performed and adhered to
(ii)Whether ’intention to treat’ analysis was performed by authors,
possible from data but not performed by authors, not possible or
uncertain
(f ) Criteria for hysterectomy
(i) Indications specified
(ii) Data broken down by indications for hysterectomy
(B) Characteristics of the study participants
(a) Baseline characteristics
(i) Age
(ii) Parity
(iii) Indication for hysterectomy
(iv) Investigative work-up, for example pelvic ultrasound scan,
endometrial sampling
(v) Previous treatments
(vi) Exclusion criteria
(b) Treatment characteristics
(i) Pre-operative preparation, for example pre-operative medical
treatment
(ii) Level of training of surgeons
(C) Interventions
(a) Total or sub-total hysterectomy
(b) Use of technique to support the vaginal vault
(c) Proportion undergoing bilateral elective oophorectomy versus
ovarian conservation
(d) Other strategies to reduce the likelihood of complications
(e) Absence of co-interventions in treatment and control groups
(f ) If the trial compares a surgical approach performed by one
(group of ) surgeon(s) with another surgical approach performed
by a second (group of ) surgeon(s).
(D) Outcomes
(1) Operating time
(2) Immediate complications of surgery:
(a) Surgical injury
(i) Urinary tract (bladder or ureter) injury
(ii) Bladder injury
(iii) Ureter injury
(iv) Bowel injury
(v) Vascular injury
(f ) Bleeding
(g) Unintended laparotomy for approaches not involving routine
laparotomy
(3) Short-term outcomes:
(a) Pain
(b) Sequelae of bleeding:
(i) Haemoglobin/haematocrit drop
(ii) Transfusion
(iii) Pelvic haematoma
(c) Infection:
(i) Vaginal cuff
(ii) Abdominal wall or wound
(iii) Urinary tract infection (UTI)
(iv) Febrile episodes or unspecified infection
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(d) Thrombo-embolism
(e) Perioperative mortality
(4) Recovery from surgery:
(a) Length of hospital stay
(b) Return to normal activities
(5) Long-term outcomes:
(a) Fistula
(b) Pelvi-abdominal pain
(c) Urinary dysfunction
(d) Bowel dysfunction
(e) Pelvic floor condition (prolapse)
(f ) Sexual dysfunction
(g) Satisfaction/quality of life
(6) Cost
Data Management
All data were extracted independently by at least two reviewers
(fromET,EC,ALandNJ) anddifferences of opinionwere resolved
by consensus after consultation with another reviewer. Additional
information on trial methodology or actual original trial data was
sought from the corresponding author of trials, in which the eligi-
bility criteria were apparently met, when aspects of methodology
were unclear, or where data were in a form unsuitable for meta-
analysis. Reminder correspondence was sent if a reply was not re-
ceived within four weeks.
Statistical Analysis
Statistical analysiswas performed in accordancewith the guidelines
for statistical analysis developed by the Menstrual Disorders and
Subfertility Group. Statistical heterogeneity between the results of
different studies was examined by inspecting the scatter in the data
points on the graphs and the overlap in their confidence intervals
and, more formally, by checking the results of chi2 tests and I2
tests. The outcomes were pooled statistically where no clinical
heterogeneity was apparent. A fixed-effect model was used where
statistical heterogeneitywas absent.Where statistical heterogeneity
was apparent after pooling of data, this was noted and statistically
significant results interpreted cautiously after further analysis using
a random-effects statistical model.
Dichotomous data were expressed as an odds ratio with 95% con-
fidence intervals and combined for meta-analysis with RevMan
software using the Peto-modified Mantel-Haenszel method. An
increase in the odds of a particular outcome is displayed graph-
ically in the meta-analyses to the right of the centre-line and a
decrease in the odds of an outcome is displayed graphically to the
left of the centre-line.
Continuous data were combined for meta-analysis with RevMan
software using the weighted mean difference (WMD) with 95%
confidence interval.
It was planned to perform sensitivity analyses to examine the sta-
bility of the results in relation to the following factors:
- exclusion of trials comparing a surgical approach performed by
one surgeon (or group of surgeons) with another surgical approach
performed by a second (group of ) surgeon(s);
- the effect of analysing studies of LH(a) sub-categories compared
to studies of LH(a) pooled as an overall category.
A search will be conducted for trials every two years and the review
updated if new trials are found.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting assessment.
Forty-two trials were identified. Nine of these were initially iden-
tified as published abstracts from conference proceedings. The
first authors of these studies were contacted in an attempt to ex-
tract details that were not reported: two studies were included (
Darai 2001;Miskry 2003), three excluded (Møller 2001;Oscarson
2003; Park 2003) and four replies have not so far been received
(Cucinella 2000; Davies 1998; Pabuccu 1996; Petrucco 1999).
These four studies, along with a further study, in Swedish, that
has been sent for translation but as yet has not been received (
Hahlin 1994), have been transferred as the five ’Studies awaiting
assessment’ to the appropriate section of the review. Ten studies
were excluded from the review; the reasons for their exclusion are
listed in the ’Characteristics of excluded studies’ table. The authors
were able to extract data from the remaining 27 trials, of which
two compared VH versus AH (Benassi 2002; Miskry 2003), 16
compared LH versus AH (including one LH-BSO versus AH-
BSO (Raju 1994)); four compared LH versus VH (Darai 2001;
Richardson 1995; Soriano 2001; Summitt 1992); one compared
LAVH versus LH(a) (Long 2001); one compared both LH versus
AH and LH versus VH (Garry 2004); three compared LH versus
AH versus VH (Hwang 2002; Ottosen 2000; Ribiero 2003).
Participants
The 27 included trials contained 3,643 participants, the majority
from the age range of 41 to 50 years. Twenty-one trials reported no
dropouts. Two trials had participants withdraw pre-operatively:
Falcone 1999 (4out of 48) andGarry 2004 (34out of 1380). In the
Lumsden 2000 study, seven participants withdrew pre-operatively
and case recordswere not available for threemore. Twoparticipants
refused their assigned procedure in the Summitt 1998 study; in
the Yuen 1998 study, four participants declined their assigned
operation and a further two participants refused to participate
post-operatively. In the Long 2001 trial, three women undergoing
conversion to laparotomy, sevenwith incomplete records and three
with combined procedures were excluded post-randomisation. A
further 53 were excluded because they did not have indications of
uterine fibroids or adenomyosis.
All of the included trials recruited women who needed a hysterec-
tomy for benign causes; six studies specifically included women
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who underwent hysterectomy for symptomatic uterine fibroids (
Benassi 2002; Ferrari 2000; Hwang 2002; Long 2001; Ribiero
2003; Tsai 2003).
VH versus AH
Benassi 2002 specifically included women with symptomatic en-
larged fibroid uteri and excluded women with prolapse, vaginal
stenosis, neoplasia, previous pelvic surgery and those taking hor-
mone treatments within 6 months prior to surgery. Miskry 2003
excluded women with uterine size greater than 14 weeks gestation,
malignancy, adnexal pathology, reduced uterine mobility or re-
duced vaginal access and any woman requiring concomitant pro-
lapse or incontinence surgery.
LH versus AH (including LH-BSO versus AH-BSO)
Eleven of the 16 studies that compared LH with AH specifically
included participants who were scheduled for an abdominal hys-
terectomy or who had contraindications for a vaginal hysterec-
tomy (Ellstrom 1998; Harkki-Siren 2000; Falcone 1999; Ferrari
2000; Lumsden 2000; Marana 1999; Olsson 1996; Seracchioli
2002; Summitt 1998; Tsai 2003; Yuen 1998). Contraindications
to vaginal hysterectomy included the size of the uterus: greater
than 14 weeks of pregnancy (Lumsden 2000; Seracchioli 2002),
uterine volume greater than 200 ml (Ferrari 2000), greater than
300 g (Seracchioli 2002), greater than 280 g (Marana 1999) or
200 g (Schutz 2002); limited vaginal access (Ferrari 2000;Marana
1999); lack of uterine descent (Marana 1999); immobile uteri (
Ferrari 2000); previous pelvic surgery or a history of pelvic inflam-
matory disease (Ferrari 2000; Marana 1999).
Eleven studies excluded participants according to their uterine
size or width: uterine size greater than a 12-week pregnancy (
Langebrekke 1996), greater than a 14-week pregnancy (Harkki-
Siren 2000; Lumsden 2000; Perino 1999; Raju 1994), greater
than a 16-week pregnancy (Marana 1999; Tsai 2003; Yuen 1998)
and greater than an 18-week pregnancy (Summitt 1998). Ellstrom
1998 and Olsson 1996 excluded participants with a uterus width
greater than 11 cm, whilst Harkki-Siren 2000 excluded women if
the uterine width was greater than 10 cm.
Participants were excluded for various physiological/anatomical
reasons: pubic arch of at least 90 degrees (Summitt 1998), uter-
ine prolapse (Harkki-Siren 2000; Raju 1994; Seracchioli 2002),
pelvic floor relaxation (Seracchioli 2002); immobile uteri (Ferrari
2000); and medical reasons: morbidly obese (Harkki-Siren 2000;
Raju 1994), suspicious adnexal mass or malignant disease (
Falcone 1999;Marana 1999; Langebrekke 1996; Seracchioli 2002;
Summitt 1998), severe pelvic disease including adhesions and
endometriosis (Ferrari 2000; Harkki-Siren 2000; Olsson 1996;
Summitt 1998), concomitant incontinence procedure, pelvic re-
construction or colporrhaphy required (Falcone 1999;Summitt
1998) or if the participants had any serious diseases including car-
diopulmonary disease, bleeding disorders etc (Harkki-Siren 2000;
Langebrekke 1996; Seracchioli 2002; Summitt 1998).
LH versus VH
Two of the four studies that compared LH with VH included
participants if their uterine size was larger than 280 g (Darai 2001;
Soriano 2001). The remaining two studies excluded studies if their
uterine size was greater than a 16-week pregnancy (Richardson
1995; Summitt 1992).
Exclusions for physiological/anatomical reasons: pubic arch of at
least 90 degrees (Summitt 1992), narrow vagina (Darai 2001),
immobile uteri (Darai 2001; Summitt 1992); and medical rea-
sons: suspicious adnexal mass or malignant disease (Darai 2001;
Richardson 1995; Soriano 2001), severe pelvic disease including
adhesions and endometriosis (Richardson 1995; Soriano 2001),
concomitant incontinence procedure, pelvic reconstruction or col-
porrhaphy required (Summitt 1992) or if the participants had any
serious diseases including cardiopulmonary disease, bleeding dis-
orders etc (Summitt 1992).
VH versus LH (vLH as it was called in the trial) and AH versus
LH (aLH as it was called in the trial)
Garry 2004 included participants scheduled for hysterectomy for
non-malignant conditions. The same exclusion criteria were used
for both arms of the trial: a uterine mass greater than the size of
a 12-week pregnancy, suspected malignant disease of the genital
tract, uterine prolapse, serious medical illness precluding surgery,
requirement for bladder or other pelvic support surgery.
LH versus AH versus VH
Two of the three trials (Hwang 2002; Ribiero 2003) specifically
included those with uterine fibroids. Ottosen 2000 included par-
ticipants with leiomyomas <15 cm in diameter; Hwang 2002 in-
cluded women with a myoma diameter larger than 8 cm and the
second myoma less than 5 cm or two myomata, both at least 6
cm in diameter but less than 8 cm (a maximum of three my-
omata); Ribiero 2003 included women with fibroids or adeno-
myosis. Ottosen 2000 excluded those with a uterine mass larger
than 16weeks of gestational size, previous dense adhesions, narrow
vagina or inaccessible uterus. Hwang 2002 excluded those with
indications of adenomyosis, uterine prolapse, chronic pelvic pain,
dysfunctional uterine bleeding, cervical dysplasia or PID. Ribiero
2003 excluded women with uterine volume greater then 400 mls,
those taking anti-inflammatories, and women with diabetes mel-
litus, coagulation disorders and autoimmune disease.
LAVH versus LH(a)
In Long 2001, participants were included if they had contraindi-
cations for vaginal hysterectomy (a uterine weight >280 g, pre-
vious pelvic surgery, PID, need for adnexectomy, lack of uterine
descent and limited vaginal access). If their uterine volume was
greater than a 16 week pregnancy (or weight greater than 700 g)
they were excluded.
Interventions
Surgical procedures
LH versus AH
Twenty trials included a comparison of laparoscopic hysterectomy
(LH) with abdominal hysterectomy (AH). These included four
trials that randomised women to LH, AH and VH (Garry 2004;
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Hwang 2002; Ottosen 2000; Ribiero 2003). Raju 1994 compared
LH and bilateral salpingo-oophorectomy (LH-BSO) with AH-
BSO. Ellstrom 1998 stratified the two randomised groups (LH
and AH) into total and subtotal hysterectomies.
LH versus VH
Eight trials included a comparison of laparoscopic hysterectomy
(LH) with vaginal hysterectomy (VH), including, again, the four
trials randomising women to LH, AH and VH. Garry 2004 was a
very large RCT comparing LH (called vLH in the trial) with VH
and LH (called aLH in the trial) with AH - it was essentially two
concurrent RCTs as part of the same study.
LAVH versus LH(a)
Long 2001 compared two types of laparoscopic hysterectomy,
LAVH versus LH(a).
Although all the trials used variations of the terms “laparoscopic as-
sisted vaginal hysterectomy” (’LAVH’) or “laparoscopic hysterec-
tomy”, their definition varied according to what stages of the hys-
terectomy were completed laparoscopically and the point at which
the operation continued vaginally. We included all trials with hys-
terectomies that had some laparoscopic component in a larger cat-
egory LH. Using Richardson 1995’s ’Staging of laparoscopic hys-
terectomy’ table (see Additional Table 2) we were able to categorise
21 of the 24 included studies that involved LH according to the
amount of laparoscopic content. We also sub-categorised these 21
trials involving LH as either LAVH, LH(a) or TLH, depending on
the extent of the surgery performed laparoscopically and vaginally
(see Additional Table 1). If any trial included women undergoing
different Richardson LH stages in the LH arm, we arbitrarily cat-
egorised the stage firstly as the stage to which the surgeons had
intended to go, secondly, if that information was not available, to
the LH stage that most women underwent, or thirdly the most ad-
vanced LH stage that women underwent. According to Richard-
son staging, one trial involved stage zero LH (Ottosen 2000), three
trials were stage two (Kunz 1996; Marana 1999; Raju 1994), two
trials were stage three (Ferrari 2000; Tsai 2003), eight trials were
stage four where the uterine artery was transected laparoscopically
(Darai 2001; Ellstrom 1998; Olsson 1996; Schutz 2002; Soriano
2001; Summitt 1992; Summitt 1998; Yuen 1998) and seven trials
were stage five (Falcone 1999; Hwang 2002; Harkki-Siren 2000;
Langebrekke 1996; Perino 1999; Ribiero 2003; Seracchioli 2002).
There were three trials in which we were unable to sub-categorise
the LH procedures and we described these as ’non-categorisable
LH’: Richardson 1995 had LHs of all stages from 0 to 5 and two
trials (Garry 2004; Lumsden 2000) did not stipulate LH stages
performed. In Long 2001, the LAVH treatment arm was a stage
three whilst the LH(a) arm was a stage five. In two trials that used
total laparoscopic hysterectomy (TLH) as an intervention (Perino
1999; Ribiero 2003), all of the surgical manipulation, including
incision and suturing of the vaginal vault, was carried out laparo-
scopically, even though the uterus was actually removed transvagi-
nally, Nezhat stage seven (Nezhat 1995).
Surgeons’ experience
The surgeons’ experience or level of training was reported in 16 of
the trials. Ten of the trials used the authors of the trial or surgeons
of senior registrar grade to perform all the operations. Five of these
trials specified that the same group of surgeons performed opera-
tions for both interventions (Benassi 2002; Long 2001; Lumsden
2000; Hwang 2002; Seracchioli 2002). In three trials, surgeons
for one intervention were different to those performing the other
intervention: Olsson 1996 (LH carried out by two out of five sur-
geons of senior registrar grade, trained in LH; AH carried out by
two out of ten surgeons of senior registrar grade, trained in AH);
Langebrekke 1996 (LH performed exclusively by the two authors,
AH performed by any skilled gynaecologist in the department);
Raju 1994 (LAVH performed by one of the authors, AH by one
of the authors or a surgeon of senior registrar grade). In Ottosen
2000,15 gynaecological surgeons with assistants performed the
operations, their experience varied and there were cases of residents
performing operations under supervision. In Schutz 2002, 71%
of LH were performed by the attending physician and 29% by
a resident under supervision and 40% of AH were performed by
the attending physician and 60% by the resident under supervi-
sion. One trial (Summitt 1998) used only gynaecological residents
to perform all the operations with the assistance of the attending
physician. It is unlikely that any of the latter three trials used the
same group of surgeons for both intervention groups. In three
other trials it was unclear if the surgeons performing the opera-
tions were different: Darai 2001 (all experienced in laparoscopic
and vaginal surgery but no mention of who performed each inter-
vention); Perino 1999 (LH: team of three laparoscopic surgeons
with experience of more than 100 LHs, no details provided for
AH arm) and Falcone 1999 (one of the senior authors performed
all the LH operations with the assistance of a pelvic surgery fellow
or resident but no mention of the AH group). In four of the trials,
surgeons of all grades and experience carried out the operations.
In Garry 2004, each surgeon recruited to the trial had to have
performed 25 of each procedure however cases could be used for
teaching if the main assistant was the designated surgeon.
Antibiotic prophylaxis/Anticoagulant therapy
In 18 of the trials the use of antibiotic prophylaxis was reported.
Thirteen trials prescribed the following antibiotics pre-opera-
tively: Cefazoline 2 g IV (Darai 2001; Soriano 2001; Summitt
1992; Summitt 1998); Cephalosporine 2 g IV (Langebrekke 1996;
Kunz 1996); Metronidazole 500 mg IV (Harkki-Siren 2000);
Cephalosporine and metronidazole IV (Ellstrom 1998; Olsson
1996; Richardson 1995); Cefuroxime 1.5 g IV and metronidazole
1 g rectally (Ottosen 2000); Cefotaxime 2 g IV (Benassi 2002);
Co-amoxiclav 1.2 g IV (Miskry 2003); Ampicillin 2 g (Seracchioli
2002) and Piperacillin 2 g IV (Lumsden 2000).
Long 2001 prescribed cefazolin 1 g IV pre and post-operatively.
Raju 1994 gave Amoxillin clavulanate (Augmentin) bolus IV dur-
ing and for seven days following the operation. Hwang 2002 pre-
scribed cephalosporin 1 g every 8 hours combined with amino-
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glycoside 80 mg every 12 hours for one day after surgery.
In Olssen 1996, antibiotics were used in the laparoscopic arm of
the study but they were not routinely given for the abdominal
hysterectomies.
The use of low molecular weight heparin was reported in six trials:
three trials prescribedheparin pre-operatively (Benassi 2002;Darai
2001; Soriano 2001) and three post-operatively (Langebrekke
1996; Miskry 2003; Ottosen 2000).
Anaesthesia and post-operative medication
Eighteen trials specifically stated that all hysterectomies were com-
pleted under general anaesthesia (GA). In two trials, GA was used
for all LHs but the choice of regional or general anaesthesia was left
to the anaesthesiologists and patients for the AH or VH (Summitt
1992; Summitt 1998). In Ottoson 2000, 109 of the 120 included
participants were operated on using GA, three had spinal blockade
and 8 had spinal blockade in combination with epidural blockade.
Benassi 2002 used GA for AH procedures, spinal anaesthetic for
VH. Five trials did not report the anaesthetic technique used.
Fifteen trials reported on the type of post-operative pain relief
given to participants. In six trials morphine was used, two via
intramuscular morphine sulphate injections (Raju 1994; Soriano
2001); three via a programmable infusion pump (Ellstrom 1998;
Falcone 1999; Yuen 1998) and in Olsson 1996 details of how the
morphine was administered were not reported. In Hwang 2002
meperidine 50 mg IV was prescribed every four hours. Long 2001
administered lysine aspirin intravenously.
The use of oral or rectal analgesics was reported in 11 trials:
Summitt 1992 and Summitt 1998 discharged participants with
16 tablets of acetaminophenoxycodone; Raju 1994 gave rectal di-
clofenac immediately after surgery, followed by coproxamol or
codidramol; Ellstrom 1998 and Hwang 2002 prescribed parac-
etamol; Soriano 2001: 2 g propacetamol and 100 mg ketopro-
fen started 30 to 60 minutes before completion of the operation
and then every six hours for 24 hours followed by acetaminophen
(paracetamol); Falcone 1999: Oxycodone 5 to 10 mg every 4 to 6
hours as needed then 325 to 650 g acetaminophen (paracetamol)
every 4 to 6 hours as needed; Kunz 1996 prescribed Tramadol hy-
drochloride (100 mg); Marana 1999 and Perino 1999:Ketorolac
every six hours for the first 24 hours. The use of anti-emetic
drugs was reported in three trials (Summitt 1992; Summitt 1998;
Ellstrom 1998).
Outcomes
All of the trials assessed the operation times and intra- or post-
operative complications. Lumsden 2000 and Garry 2004 split the
complications into major and minor. The majority (22 trials) as-
sessed blood loss or haemoglobin change. Ellstrom 1998 reported
on the difference in erythrocyte volume fraction. Febrile morbid-
ity was measured in eight trials, pulmonary function in one trial (
Ellstrom 1998) and nine trials reported any operations that were
converted to abdominal surgery (Darai 2001;Garry 2004;Marana
1999; Ottosen 2000; Richardson 1995; Seracchioli 2002; Soriano
2001; Summitt 1992; Summitt 1998).
Postoperative pain was assessed in 11 trials, with Ellstrom 1998
listing it as a primary outcome. Twenty-four trials assessed the
length of post-operative hospital stay and nine included an analysis
of costs. Recovery time or the time needed to return to normal
activities/work was assessed in 12 trials. An assessment of health
status was reported in six trials, two trials included sexual activity
or body image in the analysis (Garry 2004; Long 2001).
The selective reporting of ’interesting’ results must be emphasised
as it is a concern that potentially jeopardises the reliability of con-
clusions both from the individual studies and from this review.
Risk of bias in included studies
Study design
All of the included trials had a parallel group design. Twenty of the
trials were single centre studies (four from Italy; three each from
Sweden and Taiwan; two each from the UK, USA and Germany;
and one each from Brazil, Finland, France and Hong Kong). Of
the sevenmulti-centre trials, three trials recruited from two centres
(Darai 2001 based in France, Langebrekke 1996 based in Norway
andMiskry 2003 based in theUK). Two trials recruited from three
centres (Summitt 1998 based in theUSA andLumsden 2000 based
in the UK). One trial from Italy (Marana 1999) recruited from
four centres and a trial based in the UK with additional centres in
South Africa (Garry 2004) recruited from 30 centres.
Randomisation and allocation concealment
Six studies randomised by computer and used sealed opaque en-
velopes for allocation concealment (Ferrari 2000; Hwang 2002;
Miskry 2003; Ottosen 2000; Raju 1994; Summitt 1998). Two
trials randomised by computer and used a telephone for alloca-
tion concealment (Garry 2004; Schutz 2002). Langebrekke 1996
used a table of random digits for randomisation and used sealed
opaque envelopes for allocation of concealment. Nine trials used
a computer generated randomisation code (Benassi 2002; Darai
2001; Falcone 1999; Lumsden 2000; Marana 1999; Seracchioli
2002; Soriano 2001; Summitt 1992; Tsai 2003; Yuen 1998) and
one trial used a random numbers table (Richardson 1995) but
none of these 10 trials reported whether allocation was concealed.
Two trials used sealed opaque envelopes for allocation of treatment
but they did not report the randomisation method (Harkki-Siren
2000; Olsson 1996). Five trials did not report the randomisation
method or if it was concealed (Ellstrom 1998; Kunz 1996; Long
2001; Perino 1999; Ribiero 2003). The methodological quality
of the Long 2001 trial was suspect. Participants were randomised
to treatment groups before a large number (66) of them were
excluded. Therefore the participants in each treatment group are
not a true representation of the original randomised groups.
In 11 studies allocation concealment was adequate and graded A
(according to Cochrane criteria). In 16 studies the methods to
conceal randomisation were not reported and allocation conceal-
ment was graded B (unclear).
Blinding
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Blinding was not reported by any of the trials and was unlikely.
Intention-to-treat
Twenty-one trials reported no dropouts. Six trials reported
dropouts, ranging from a dropout rate of 2.5 to 12%. Table 4
lists the trials that reported dropouts with the dropout circum-
stances. Of the six RCTs reporting dropouts, two reported analysis
by intention-to-treat (ITT), defined as all randomised women re-
ported upon according to group of randomised allocation (Falcone
1999; Garry 2004). Four RCTs reporting dropouts did not report
ITT analysis of all randomised participants (Long 2001; Lumsden
2000; Summitt 1998; Yuen 1998). In the Long 2001 trial, al-
though reasons were given for 13 participants who were excluded,
it was not clear why an additional 53 had been excluded. One fur-
ther trial that had no dropouts did not analyse by ITT but accord-
ing to treatment received that was different to treatment assigned
in two cases - the operation was converted from LH to AH and
these participants were analysed in the AH group (Tsai 2003).
Power calculations for sample size
Fifteen of the studies did not report that a power calculation was
performed for sample size. The only trial to report a credible,
prospective power calculation that sought realistic differences (us-
ing major complications as the primary outcome) was Garry 2004
and this was by far the largest included trial (n = 1380). The re-
cruitment target was met in the LH versus AH arm, but not in
the LH versus VH arm.
Table 4. Studies reporting dropouts
Trial No. dropouts Details
Falcone 1999 4 (1 LH; 3 AH) Withdrew pre-operatively
Garry 2004 34 (23 LH (11 aLH; 12 vLH); 6 AH; 5 VH) Withdrew pre-operatively
Long 2001 13 3 laparotomy conversions; 7 incomplete records; 3 combined pro-
cedures that were excluded pot-randomisation
Lumsden 2000 10 7 withdrew pre-operatively; 3 case reports not available
Summitt 1998 2 Refused assignment procedure
Yuen 1998 6 4 declined operation; 2 refused to participate post-operatively
Source of funding
Nine studies reported their sources of funding. Two of these stud-
ies received funding from pharmaceutical or surgical instrumen-
tation companies: Summitt 1998 received all of its funding from
US Surgical Corporation, USA and Harkki-Siren 2000 received
a part of its funding from the Research Foundation of the Orion
Corporation.
Effects of interventions
Meta-analysis results
Where outcomes for specific comparisons included in the meta-
analysis are not mentioned below, no data were available from the
included trials. For results that were not statistically significant, the
summary statistics and confidence intervals have not been stated
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in the text, but may be viewed on the meta-analysis graphs.
Operation time
Both trials in the meta-analysis of VH versus AH showed a signif-
icant difference, but in opposite directions, thus the results were
not pooled. AHhad a significantly shorter operation time than LH
(WMD 10.6 minutes, 95% CI 7.4 to 13.8 minutes), although it
was noteworthy that in the sub-category of trials where LAVHwas
compared with AH, LAVH operations were significantly shorter
than AH (WMD 7.6 minutes , 95% CI 3.0 to 12.2 minutes). Sta-
tistical heterogeneity was present for operation time for LH versus
AH (chi2 p-value 0.00001, I2 = 96.2%), but similar results were
obtained with a random-effects model, other than the difference
in operating time between the LAVH sub-category and AH not
being significant. VH had a significantly shorter operation time
than LH (WMD 41.5 minutes, 95% CI 33.7 to 49.4 minutes)
and, although statistical heterogeneity was present (chi2 p-value
0.001, I2 = 80.6%), similar results were obtained with a random-
effects model. LAVH had a significantly shorter operation time
than LH(a) (WMD 25.3 minutes, 95%CI 10.0 to 40.6 minutes).
Intraoperative complications
Where bladder and ureter injuries were pooled as ’urinary tract
injury’, there was a significant increase in urinary tract injury for
LHversus AH (OR2.61, 95%CI 1.22 to 5.60), but no statistically
significant differences in urinary tract injury for LH versus VH
(OR 1.00, 95% CI 0.36 to 2.75) or for LH(a) versus LAVH (OR
1.60, 95% CI 0.29 to 7.83).
There were no significant differences in the occurrence of:
- bladder injury betweenVHversus AH, LHversus AH, LHversus
VH, or LH(a) versus LAVH;
- ureteric injury betweenVHversus AH, LHversus AH, LHversus
VH, or LH(a) versus LAVH;
- bowel injury between VH versus AH, LH versus AH, LH versus
VH, or LH(a) versus LAVH;
- vascular injury between LH versus AH, LH versus VH, or LH(a)
versus LAVH;
- mean blood-loss between VH versus AH and number of women
with substantial bleeding between LH versus AH and LH versus
VH;
- unintended laparotomy between LH versus VH, or LH(a) versus
LAVH.
Short term complications
For VH versus AH, there were significantly fewer unspecified in-
fections or febrile episodes (OR 0.42, 95% CI 0.21 to 0.83). For
LH versus AH, there were significantly fewer wound or abdominal
wall infections (OR 0.32, 95% CI 0.12 to 0.85) and significantly
fewer unspecified infections or occurrence of pyrexial illness (OR
0.65, 95% CI 0.49 to 0.87).
There were no significant differences in:
- the need for blood transfusion for VH versus AH, LH versus
VH, LH(a) versus LAVH (and the difference in mean blood loss
and haemoglobin drop for these comparisons was not statistically
significant); although LH and AH showed no significant differ-
ence in the need for blood transfusion, LH was associated with
a significantly lower mean blood loss (WMD 45.3 mls, 95% CI
17.9 to 72.7 mls) and smaller drop in haemoglobin (WMD 0.55
g/L, 95% CI 0.28 to 0.82 g/L);
- occurrence of pelvic haematoma or vaginal cuff infection for
VH versus AH, LH versus AH, LH versus VH, or LH(a) versus
LAVH;
- UTI for VH versus AH, LH versus AH, LH versus VH;
- chest infection for VH versus AH, LH versus AH, LH versus
VH;
- other unspecified infection or pyrexial illness for LH versus VH,
or LH(a) versus LAVH;
- thrombo-embolic events for LH versus AH, LH versus VH.
Other short term outcomes
Speedier recovery from surgery favoured VH versus AH in terms
of shorter hospital stay (WMD 1.0 day, 95% CI 0.7 to 1.2 days)
and speedier return to normal activities (WMD 9.5 days, 95%
CI 6.4 to 12.6 days) and, although statistical heterogeneity was
present with return to normal activities (chi2 p-value 0.02, I2 =
75.3%), similar results were obtainedwith a random effectsmodel.
Recovery also favoured LH versus AH (hospital stay WMD 2.0
days, 95%CI 1.9 to 2.2 days; return to normal activities WMD
13.6 days, 95%CI 11.8 to 15.4 days). Statistical heterogeneity was
present for hospital stay (chi2 p-value < 0.00001, I2 = 95.0%) and
for return to normal activities (chi2 p-value 0.004, I2 = 71.2%),
although similar results were obtained for these outcomes using
a random-effects model. There were no significant differences in
recovery from surgery, in terms of hospital stay or return to normal
activities for LH versus VH, or in terms of hospital stay for LH(a)
versus LAVH.
Long term outcomes
No significant differences were found in long term:
- fistula formation for LH versus AH, LH versus VH;
- urinary dysfunction for VH versus AH, LH versus VH;
- sexual dysfunction in terms of dyspareunia or failure to orgasm
for LH(a) versus LAVH;
- patient satisfaction for LH versus AH.
Sensitivity analyses
Exclusion of trials susceptible to ’surgeon effect’
Exclusion of the three trials in which surgeons for one interven-
tion were unequivocally different to those performing the other
intervention (Langebrekke 1996; Olsson 1996; Raju 1994) did
not alter the statistical significance of any meta-analysis results.
Sub-categorisation of LH
LAVHhad a significantly shorter operation time than AH (WMD
7.6 minutes, 95% CI 3.0 to 12.2 minutes), whilst other sub-
categories of LH took significantly longer than AH operations
(LH(a) versus AH, WMD 30.6 minutes, 95% CI 25.6 to 35.7
minutes; TLH versus AH, WMD 16.3 minutes, 95% CI 7.0 to
25.6 minutes). LH was associated with significantly fewer blood
transfusions than AH (OR 0.48, 95% CI 0.24 to 0.97). All other
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sub-category meta-analyses of LH versus AH and LH versus VH
showed results that were similar to meta-analysis of LH as a pooled
group versus AH and versus VH.
Data from included trials that were not in the meta-analysis
Data expressed as medians were not included in the meta-analysis.
Only outcomes reaching statistical significance will be mentioned
below (a full summary of results is presented in Other Data Tables
01 to 06) .
Operation time
Hwang 2002 found a significantly shorter median operating time
for VH (74 minutes) versus AH (98 minutes). In three trials (
Falcone 1999; Ferrari 2000; Raju 1994) AH had a significantly
shorter median operation time than LH. Median operating time
was significantly shorter for VH than for LH (Hwang 2002).
Intraoperative complications
For LH versus AH, median estimated operative blood loss was
significantly lower forAH inone trial (Falcone 1999) and for LH in
another (Yuen 1998).Median haemoglobin drop was significantly
lower for LH in one trial (Schutz 2002).
Short term outcomes
For LH versus AH, LH was associated with significantly lower
pain scores than AH in a number of trials (including Garry), on
postoperative days 0, 1, 2 and 3 (Marana 1999), day 2 (Olsson
1996), day 4 (Schutz 2002) and on coughing (Ellstrom 1998).
TLH was associated with significantly less severe postoperative
pain than AH (Perino 1999).
Recovery from pain was significantly faster for LH (Raju 1994).
Concerning analgesic use, LHwas associatedwith significantly less
opiate use (Garry 2004) and oral and rectal analgesia (Langebrekke
1996), shorter duration of analgesic use overall (Raju 1994) and
of patient-controlled analgesic use (Falcone 1999), fewer patients
requiring intramuscular narcotics on the day of surgery (Summitt
1998) and less analgesic use after the first 24 hours (Ferrari 2000).
Median duration of hospital stay was significantly shorter for LH
in five trials (Falcone 1999; Ferrari 2000; Langebrekke 1996; Raju
1994; Yuen 1998). Median duration of return to normal activities
was significantly shorter for LH in two trials (Langebrekke 1996;
Raju 1994).
For LH versus VH, LH was associated with significantly greater
use of oral pain tablets on postoperative day two, but no other
significant differences in pain scores or analgesic use were found.
Long term outcomes
For LH versus AH, Garry 2004 demonstrated that quality of life
(measured by SF12 scoring system) was better for LH at six weeks,
that body image was significantly improved for LH versus AH at
six weeks and four months, but not 12 months and that sexual
frequency was significantly higher at six weeks following LH.
Cost
No trial found a significant difference in the overall cost of LH
versus AH, but only five RCTs examined comparative cost in any
detail (Ellstrom 1998; Falcone 1999; Lumsden 2000; Raju 1994;
Summitt 1998). The mean total hospital cost was significantly
higher for LH than for VH (Summitt 1992).
D I S C U S S I O N
Our review found anumber of advantages ofVHoverAH.VHwas
less painful and was associated with earlier discharge from hospital
and return to normal activities. There were conflicting data on
which was the quickest operation to perform and this presumably
relates to the prior experiencewith these procedures of the surgeons
involved in the trials. LH offered a number of advantages over
AH; fewer wound or abdominal wall infections, fewer unspecified
infections or episodes of pyrexia, smaller drop in haemoglobin, less
pain, earlier discharge fromhospital and return to normal activities
and improved quality of life at six weeks and four months after
surgery; the cost was a longer operating time. LH was associated
with less postoperative pain, earlier discharge from hospital and
return to normal activities than AH, but AH required a shorter
operating time. LH had a number of disadvantages compared to
VH; a longer operating time, greater use of oral pain tablets on
day two and a higher hospital cost. There were no significant
differences between LH(a) and LAVH.
Speed of recovery is determined by avoiding an abdominal proce-
dure; AH is associated with lengthier recovery than all other ap-
proaches to hysterectomy. Avoidance of AH also appears to be im-
portant to minimise postoperative pain and avoid abdominal wall
infections and infections of unspecified origin or general pyrexial
illness postoperatively.
Operating time is overall longer for LH versus AH and for LH
versus VH. However LAVHs had a significantly shorter operating
time than AH (when analysed as a sub-category) and LAVH had a
significantly shorter mean operating time than LH(a). These data
suggest that operating time seems to be governed by the propor-
tion of the surgery performed laparoscopically; the greater pro-
portion performed laparoscopically, the lengthier the operation.
Most surgeons who are comfortable with laparoscopic techniques
will be able to undertake laparoscopic adhesiolysis or excision of
endometriosis (Richardson stage 1), free both adnexa (stage 2) and
dissect the bladder (stage 3) laparoscopically, Richardson stages 1-
3 fulfilling our definition of LAVH. Amore challenging part of the
laparoscopic procedure, that would fulfil our definition of LH(a),
is laparoscopic uterine artery transection (stage 4) and anterior or
posterior colpotomy or the complete freeing of the uterus laparo-
scopically (stage 5). Yet more expertise is required to complete a
TLH. Although it could be speculated that laparoscopic uterine
artery ligation is the manoeuvre most likely to increase the risk
of ureteric injury, especially during the learning curve for such
surgery, we were unable to confirm this since trials of LAVH versus
AH did not report on ureteric injury.
Of the 24 trials comparing LHwith either AH or VH, 21 supplied
sufficient information to categorise according to Richardson stages
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(Richardson 1995) and thus to fulfil the requirements of our sub-
categorisation. Six trials involved LAVH, 13 trials involved LH(a)
with laparoscopic uterine artery transection but still included a
vaginal component and two trials involved TLH (stage 5).
A significantly higher incidence of urinary tract damage has been
reported with hysterectomies involving the laparoscopic approach
(Garry 2004; Garry 1995; Harkki-Siren 1997). Although this
meta-analysis of RCTs was underpowered to detect a clinically sig-
nificant increase in the incidence or bladder damage and ureter
damage from a laparoscopic approach. Much of the data for an
increased incidence of urinary tract injury has come from non-
randomised studies. Whilst it could be argued that only large case
series usually have the power to detect such a rare complication,
there is anundoubted tendency toward bias from such an approach
and RCTs remain the least biased way to assess not only bene-
fits of an intervention, but also harms. When bladder and ureter
injuries in our meta-analysis were pooled under a single category
’urinary tract injury’, a significant increase in urinary tract injury
was detected for LH versus AH (OR 2.61, 95% CI 1.22 to 5.60).
Urinary tract damage, in particular ureteric injury, remains the
major concern related to the laparoscopic approach. Furthermore,
in the largest RCT included in this review, Garry 2004 elected to
pool cases in which at least one major complication occurred and
did find a significant increase in this outcome for LH versus AH
(but not LH versus VH).
Particularly difficult to address is the issue surrounding effective-
ness and complications in surgical procedures where the skill base
of surgeons is not only variable, but different between the sur-
geons’ experience of ’traditional’ operations and their experience
of ’laparoscopic’ operations. This is likely to be especially rele-
vant to the rates at which complications, such as ureteric damage,
occur. There is no good way of taking into account the risk of
such rare complications in surgeons who are beyond their learning
curve. In the current state of gynaecological practice and training,
all training gynaecologists tend to become thoroughly trained in
’traditional’ hysterectomy techniques, but there is huge variation
in their learning curve position in relation to ’laparoscopic’ hys-
terectomy techniques. This is not just a hysterectomy issue but
pervades many aspects of surgical therapy involving innovations.
It does not apply to anything like the same extent where drug
therapy interventions are being studied, in which the efficacy is
much less dependent on the skill of the investigator providing the
treatment. It is on the medical model of intervention that much
of the Cochrane methodology is developed. The heterogeneity in
such outcomes as operating time, even when the ’traditional’ hys-
terectomy techniques VH versus AH are compared, directly re-
lates to the fact that some surgeons are better trained in, and thus
perform faster, VH, and some AH. This heterogeneity might be
expected to be even more apparent when LH is compared with
either AH or VH.
Whether it is reasonable to prioritise outcomes as primary or sec-
ondary in advance is controversial. There is certainly scope for
the authors of individual RCTs to report only the outcomes that
they consider to have produced interesting results, resulting in re-
porting bias. Usual Cochrane policy is to term the most clinically
relevant outcome as ’primary’ rather than the one most obviously
affected by the treatments under comparison. Perhaps the most
plausible primary measure of effectiveness is ’return to normal ac-
tivity’ (where VH and LH fare most favourably). ’Major lasting
problem’ could perhaps be considered as the primary adverse event,
but data on all long term outcomes in these RCTs are sparse. It is
intended to define these outcomes as ’primary’ in future updates
of this review. Short-term outcomes (such as minor infections) are
interesting but of secondary importance, however ’clinical indi-
cators’ traditionally used as a measure of the level of function of
an individual clinician performing hysterectomy include visceral
injury and blood transfusion.
The approach to hysterectomy in any given case will inevitably
differ amongst gynaecologists. This is largely based on each sur-
geon’s experience and expertise with the various approaches. Until
the last few years, the vast majority of hysterectomies were per-
formed abdominally (Vessey 1992; Hall 1998; Reich 2003) and
this is likely still to be the case in most settings (Farquhar 2002).
The many advantages demonstrated from avoiding AH in this re-
view, suggest that AH should be avoided if it is possible and safe
to do so. Whilst many gynaecologists in training are now exposed
to laparoscopic approaches to hysterectomy, very few contempo-
rary newly trained gynaecologists will have sufficient expertise and
confidence to tackle TLH, which requires the highest level of sur-
gical skill. More will be trained to accomplish LAVH (and indeed
some gynaecologists who did not receive ’training’ have acquired
the skills to perform LAVH and LH(a)). Although it has been sug-
gested that LAVH does little more than to combine the complica-
tions of laparoscopic surgery with those of vaginal surgery (Reich
2003), this has not been supported in our review. There is also
a much larger database of trial experience involving LAVH than
TLH and that this undermines the extent to which conclusions
may be drawn about TLH currently.
One vital conclusion from our review must be that VH remains
a very good option - we have not shown any significant disadvan-
tages of VH versus any other approach. If VH can be achieved
in preference to AH, it should be performed. Is there any reason
to carry out LH procedures where VHs are achievable? The con-
cepts that LH allows identification of pelvic disease (such as ad-
hesions and endometriosis) which could otherwise lead to com-
plications with VH and that the meticulous haemostasis achiev-
able with ’final-look’ laparoscopy during LH might reduce pelvic
haematomas or vaginal cuff infections have not been borne out in
the outcomes in this review. Where oophorectomy is desired, a la-
paroscopic approach may facilitate this. It is uncertain whether the
increased detection of unexpected pathology at LH versus VH (
Garry 2004) affects subsequent clinical outcomes. One important
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benefit of introduction of LAVH and LH(a) into gynaecologic
training has been to increase surgeons’ confidence and skill with
vaginal surgery, thus making VH amore feasible option for many.
It also remains for the enthusiasts promoting TLH to demonstrate
its efficacy and safety in comparison to VH.
What is certain is that each gynaecologist (as has been the case
since AH became the alternative to VH in 1863) will have their
own indications for the choice of approach to hysterectomy for be-
nign disease, based largely on their own array of surgical skills and
patient characteristics such as uterine size and descent, extrauter-
ine pelvic pathology, previous pelvic surgery, with other features
such as obesity, nulliparity and the need for oophorectomy being
influential. Whether there will be more of a consensus regarding
these indications in the future than there has been to date is less
certain.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When technically feasible, VH should be performed in preference
to AH because of more rapid recovery and fewer febrile episodes
postoperatively. Where VH is not possible, LH has some advan-
tages over AH (including less operative blood-loss, more rapid re-
covery, fewer febrile episodes and wound or abdominal wall infec-
tions) but these are offset by longer operating time and more uri-
nary tract (bladder or ureter) injuries. No advantages of LH over
VH could be found and LH operations took longer. Of the three
sub-categories of LH, there are more RCT data for LAVH and
LH(a) than for TLH, the latter being themost recently introduced
approach to hysterectomy. The surgical approach to hysterectomy
should be decided by a woman in discussion with her surgeon in
light of the relative benefits and hazards.
Implications for research
The newest approach to hysterectomy (TLH) should be further
evaluated versus AH and versus VH.Whether TLH has any bene-
fits or harms in comparison to other forms of LH (including LH(a)
and LAVH) remains unclear. The increase in the rate of ureteric
injury resulting from LH, suggested by very large observational
studies, remains to be conclusively proven by RCT data.
Although it is important that RCTs should have the same surgeon
(or group of surgeons) carrying out each of the approaches being
compared, different levels of expertise with each approach means
that such RCTs are always likely to be statistically heterogeneous
when considered for pooling in meta-analyses.
We strongly encourage trial authors to report their laparoscopic
approach tohysterectomy according to our defined sub-categories:
(i) laparoscopic assisted vaginal hysterectomy (LAVH), where part
of the hysterectomy is performed by laparoscopic surgery and part
vaginally, but the laparoscopic component of the operation does
not involve division of the uterine vessels;
(ii) laparoscopic hysterectomy (LH(a)), where the uterine vessels
are ligated laparoscopically but part of the operation is performed
vaginally;
(iii) total laparoscopic hysterectomy (TLH), where the entire op-
eration (including suturing of the vaginal vault) is performed la-
paroscopically and there is no vaginal component.
This should minimise the confusion that has prevailed in the lit-
erature to date.
There is an absence of data for long term outcomes in RCTs com-
paring surgical approached to hysterectomy. RCTs should aim to
report long term outcomes, including urinary, bowel and sexual
function, along with occurrence of fistulae.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Benassi 2002
Methods Randomisation: computer selected randomisation. Single centre study, parallel group design with no
blinding.
Number of women randomised = 119. No dropouts reported.
No power calculation reported.
Source of funding: not reported.
Participants 119 women with a mean age of 47 years for the AH group and 48 years for the VH group.
Participants were recruited from a university hospital in Parma, Italy.
Inclusion criteria: Women with symptomatic enlarged uteri (200-1300 mls).
Exclusion criteria: prolapse, uterine or adnexal neoplasia, pelvic inflammation, vaginal stenosis, previous
pelvic or vaginal procedures, hormonal treatment in the 6 months prior to surgery.
Interventions AH versus VH.
AH and VH performed according to Novak technique.
Perimenopausal patients also underwent bilateral oophorectomy.
Both groups received prophylactic antibiotic treatment (Cefotaxime 2 g IV) and anticoagulant therapy
with Enoxaparin 2000 IU.
GA for AH; spinal anaesthetic for VH. The same surgeons carried out the surgery.
Duration: June 1997 - December 2000.
Outcomes Operative time; operative complications (injury to major vessel, ureter, bladder and bowel); drop in
haemoglobin; postoperative complications; hospital stay.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Darai 2001
Methods Randomisation: pre-determined computer generated randomisation code. Multicentre study (n=2), par-
allel group design with no blinding.
Number of women randomised = 80. No dropouts reported.
Power calculation to estimate sample size performed, 35 participants required for each surgery arm (as-
suming that the incidence of complications in women who had LH(a) was 10% and there was an increase
of complication rate to 40%), with an alpha (type I error) of 0.05 and a beta (type II error) of 0.2.
Source of funding not reported.
Participants 80 women with a mean age of 50 years for the LH(a) group and 49 years for the VH group.
Participants recruited from 2 hospitals in Paris, France.
Inclusion criteria: Women scheduled for abdominal hysterectomy for benign disease with traditional
contraindications for VH, including uterine size larger than 280 g and one or more of the following:
previous pelvic surgery, history of pelvic inflammatory disease (PID), moderate or severe endometriosis,
concomitant adnexal masses, indication for adnexectomy, and nulliparity without uterine descent.
Exclusion criteria: Anaesthetic contraindications for laparoscopic surgery; suspicious adnexal mass on
ultrasound; ovarian blood flow and tumour markers; vaginal narrower to less than two fingers wide;
immobile uterus with no descent and no lateral mobilization.
Interventions VH versus LH [LH(a)].
LH(a) arm (considered LH type IV): included coagulation and sectioning of the round ligament, utero-
ovarian ligaments with fallopian tubes when ovaries were conserved, and the infundibulopelvic ligaments
when ovaries were removed; opening of the bladder flap and bladder dissection, uterosacral ligaments,
base of cardinal ligaments, and uterine vessels.
Vaginal phases included circular incision of the vagina and, when necessary, wedge morcellation, coring,
or bivalving. Peritoneal closure and closure of the vaginal vault concluded the vaginal phase, at which time
the pelvis and abdomen were reevaluated through the laparoscope to be sure of hemostasis and for pelvic
lavage.
VH arm: according to modified Heaney technique.
Both groups received prophylactic antibiotic treatment (cefazoline 2g IV) at the beginning and anticoag-
ulant therapy with low molecular weight heparin the evening before the operation.
Endotracheal GA. Surgeons experienced in laparoscopic and vaginal surgery completed all the operations.
Follow up: 6-8 weeks after surgery.
Duration: January - December 1999 (1 year)
Outcomes Intraoperative and postoperative complications; febrile morbidity; analgesia requirement; postoperative
hospital stay; conversion to laparotomy; uterine size and weight.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Ellstrom 1998
Methods Randomisation: method not stated and allocation concealment not reported. Single centre study, parallel
group design with no blinding.
Number of women randomised = 40. No dropouts reported.
No power calculation for sample size was reported.
Source of funding: Goteborg Medical Society Fund, Swedish Medical Research Council.
Participants 40womenwith amean age of 46 years (LH(a) group) and 48 years (AHgroup), recruited fromSahlgrenska
University Hospital, Sweden.
Inclusion criteria: scheduled for abdominal hysterectomy for benign disorders; maximum width of uterus,
measured by transvaginal ultrasound, less than 11 cm. American Society of Anaesthesiologists (ASA)
Grade 1.
Exclusion criteria: not reported.
Interventions AH versus LH [LH(a)].
Both groups stratified to total and subtotal hysterectomies.
LH(a) arm: total hysterectomy (n=14) and laparoscopic subtotal hysterectomy (n=6). The laparoscopic
part of the total hysterectomy was finished when the uterine artery and parts of the sacrouterine ligaments
were transected. The operation was then continued vaginally.
Second generation cephalosporin and metronidazole intravenously were given during the operation and
by oral administration for 2 days after surgery. With the subtotal hysterectomy, morcellation was carried
out after transection of the uterine arteries using a mechanical or an electrical morcellator. The cervical
canal was dessicated with bipolar cautery.
AHarm: total hysterectomy (n=14) and sub-total hysterectomy (n=6).With the abdominal hysterectomies,
standard surgical techniques were used. A lower midline or Pfannenstiel incision was made. The type of
incision was left to the individual surgeon and patient to decide.
Both groups received standardized anaesthesia; Flunitrazepam (1 mg) was given as pre-medication approx
2 hrs before surgery. Anaesthesia was induced with propofol (1.5-2.5 mg per kg body weight). Morphine
(100 ug per kg body weight) was given for perioperative analgesia. Neuromuscular block was achieved
with vecuronium (0.1 mg per kg body weight). Suxamethonium (1.0 mg per kg body weight) was admin-
istrated for optimal intubation. Anaesthesia was maintained with isoflurane in oxygen/air. Morphine was
postoperatively self-administered by the patients by programmable infusion pump containing morphine
1.0mg/ml. Additional analgesic medication was restricted to paracetamol .Patients with nausea were given
10 mg metoclopramide.
Surgeon experience: not reported.
Follow up: Assessment of pain, nausea and vomiting, 8 pm day of surgery, 10 am and 6 pm first day and 10
am second postoperative day. Pulmonary function assessed pre-operatively and 10 am, first and second day.
Time of anaesthesia, surgery, per and postoperative complications and difference in erythrocyte volume
fraction (EVF) before and 2 days after surgery.
Duration: not reported.
Outcomes Primary: post-operative pain, pulmonary function.
Secondary: Time of anaesthesia, time of surgery, per and post-operative complications, difference in
erythrocyte volume fraction (EVF)
Notes
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Ellstrom 1998 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Falcone 1999
Methods Randomisation: assigned according to a computer-generated randomisation schedule with random block
sizes.
Single centre study, parallel group design with no blinding.
Number of women randomised = 48, number analysed = 44. 4 withdrew before surgery (3 AH group and
1 LH(a) group).
Power calculation performed for sample size. 22 patients per group were necessary to detect a difference
of 30 minutes or more in surgical time between the 2 groups with 90% power with a significance level of
0.05
Analysis was by intention to treat.
Source of funding: not reported.
Participants 44 women with a mean age of 42.8 years (LH(a) group) and 43.8 years (AH group). Participants were
recruited from Cleveland Clinic Foundation, Ohio USA.
Inclusion criteria: scheduled for abdominal hysterectomy for benign disease.
Exclusion criteria: pelvic mass size greater than 2 cm below the umbilicus; concomitant incontinence or
pelvic reconstructive procedures required.
Interventions AH versus LH [LH(a)].
LH(a) arm: three 10-mm trocar sites - 1 umbilical and 1 in each lower quadrant lateral to inferior epigastric
artery 6 to 8 cm above pubic rami. Uterine arteries occluded laparoscopically with electrocautery. Cardinal
ligaments cut laparoscopically. If the uterus had minimal descent, uterosacral ligaments were also cut
laparoscopically. Vagina incised either laparoscopically or vaginally, depending on the ease that this could
be achieved. Either anterior or posterior fornix, depending on access. Surgery then completed vaginally.
Vaginal cuff closed vaginally.
Performed by senior author with assistance from pelvic surgery fellow or resident.
AH arm: procedure not reported.
Follow up: daily diary for 6 weeks.
Duration: September 1995 - February 1997 (1 year, 6 months).
Outcomes Operative time; blood loss; length of hospital stay; uterine weight; intraoperative complications; postop-
erative pain; return to work/normal activities and hospital costs.
Notes
Risk of bias
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Falcone 1999 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Ferrari 2000
Methods Randomisation: Sealed opaque envelopes containing computer-generated randomisation numbers.
Single centre study, parallel group design with no blinding.
Number of women randomised = 62. No dropouts recorded. With three women in the LAVH group, the
procedure was converted to a AH. In all cases the decision was made during the laparoscopic part of the
procedure.
No power calculation for sample size was reported.
Source of funding not reported.
Participants 62 women aged from 43 to 50 years, recruited from San Paolo Biomedical Sciences Institute, University
of Milan Italy.
Inclusion criteria: symptomatic uterine fibroids.
Exclusion criteria: history of severe pelvic disease; lack of uterine accessibility and mobility or a sono-
graphically estimated uterine volume > 1500 mL (abdominal hysterectomy). Women without a history of
severe pelvic disease, with an accessible and mobile uterus and a sonographically estimated uterine volume
<500 mL, underwent a vaginal hysterectomy.
Interventions AH versus LH [LAVH].
LAVH arm: visualisation of the pelvis and upper abdomen, the treatment of adhesions or endometriosis
when present, and the completion of the upper part of the hysterectomy. Round ligaments, tubes and
utero-ovarian ligaments were desiccated and transected when the adnexa were to be preserved, while
the round and infundibulopelvic ligaments were dessicated and transected when the adnexa were to be
removed. The broad ligaments were dissected to their lower margin. When the bladder was stretched over
the anterior aspect of the uterus due to previous surgery, the bladder flap was developed laparoscopically.
The vaginal part of the hysterectomy included colpoceliotomy an bilateral ligation and transection of
utero-sacral ligaments, uterine vessels and cardinal ligaments; cervical amputation, corporal hemisection,
myomectomy and uterine morcellation were performed when necessary.
AH arm: performed according to a standard technique.
Surgeon experience: not reported.
Participants were followed up until discharge from hospital. Post-operatively, temperature and analgesic
requirement were recorded daily.
Duration: 24 months.
Outcomes Operating time; blood loss; complications; febrile morbidity; analgesic administration and hospital stay.
Notes
Risk of bias
Item Authors’ judgement Description
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Ferrari 2000 (Continued)
Allocation concealment? Yes A - Adequate
Garry 2004
Methods Randomisation: 2:1 imbalance randomisation method. Allocation to abdominal or vaginal trial by sur-
geon. Randomisation to conventional or laparoscopic approach was by telephone and performed with a
computer-generated programme.
Multicentre study (n=30), parallel group design with no blinding.
Number of women randomised: 1380.
Abdominal trial: 876 (AH: 292. aLH: 584), Vaginal trial: 504 (VH:168, vLH:336). Number of patients
that withdrew pre-operatively : AH:6, aLH:11,VH:5, vLH:12.
Power calculation to estimate sample size performed. The sample size for the abdominal trial was calculated
on the basis of 9% of AH had major complications. In order to detect a reduction complication rate of
50%, a sample size of 450 in each arm was required using 80% power and a two-sided type 1 error rate
of 5%.
Analysis by intention to treat and results were confirmed using a per-protocol analysis.
Source of funding: National Health Service Research and Development Health Technology Assessment
Programme, UK.
Participants 1380 women with a mean age of 41 years, recruited from 28 centres throughout the UK and 2 centres in
South Africa.
Inclusion criteria: Women who needed hysterectomy for non-malignant conditions.
Exclusion criteria: Confirmed or suspected malignant disease of any part of the genital tract; 2nd or
3rd degree uterine prolapse; a uterine mass greater than the size of a 12-week pregnancy; any associated
medical illness precluding laparoscopic surgery; a requirement for bladder or other pelvic support surgery
and patient refusal of consent for the trial.
Interventions 4 arms: VH, LH in the vaginal trial (vLH); AH and LH in the abdominal trial(aLH).
Surgical procedures were not reported.
Surgeons recruited had to have performed at least 25 of each type of procedure. Surgeons of all grades
and experience participated.
Follow up: 6 weeks, 4 months and 1 year.
Duration: November 1996 - September 2000 (3 years).
Outcomes Primary outcomes: major complications (major haemorrhage, bowel injury, ureteric injury, bladder injury,
pulmonary embolus, anaesthesia problems, unintended laparotomy, wound dehiscence, haematoma).
Secondary outcomes: Minor complications (major haemorrhage, anaesthesia problems, pyrexia, infection,
haematoma, DVT); blood loss; pain; analgesia requirement; sexual activity; body image; health status;
length of surgery; length of hospital stay.
Notes
Risk of bias
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Garry 2004 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Harkki-Siren 2000
Methods Randomisation: sequentially numbered, opaque and sealed envelopes. Single centre study, parallel group
design with no blinding.
Number of women randomised = 50. No dropouts reported. Tissue trauma analysis for 18 uncomplicated
hysterectomies in both groups were included.
Power calculation for sample size performed (21 women in each group would be needed for 90% study
power and for differentiation of 10 mg/L (standard deviation) between the means of C-reactive protein
(CRP) concentration when type I error is 5%. For 80% study power, 15 women in each group needed).
Source of funding: The Clinical Research Institution of Helsinki University Central Hospital and Jorvi
Hospital, The Finnish Medical Foundation and The Research Foundation of Orion Corporation.
Participants 50 women with mean age 47 years (LH(a) group) and 48 years (AH group), recruited from Jorvi Hospital,
Espoo Finland.
Inclusion criteria: scheduled for AH for benign reasons.
Exclusion criteria: major medical diseases; BMI above 32 kg/m2; size of uterus larger than of 14 weeks
of pregnancy or uterine width greater than 10 cm by transvaginal ultrasonography; severe adhesions or
endometriosis; prolapse and any other contraindications for laparoscopy.
Interventions AH versus LH [LH(a)].
LH(a) arm : A 5-mm trocar was inserted suprapubically. Pelvis was inspected and ureters located. The
uterosacral ligaments were coagulated with bipolar electrocoagulation and cut with unipolar scissors, as
were the infundibulopelvic vessels and ligaments (if adnexa were to be removed) or the round ligaments,
Fallopian tubes and utero-ovarian ligaments (adnexa not removed). The vesical peritoneum was opened
with scissors and the bladder pulled down. Uterine vessels were prepared free and divided. The anterior
fornix of the vaginawas opened laparoscopically withmonopolar scissors, the uterus was removed vaginally
and the vagina was closed with resorbable suture.
AH arm: Operated on in a standard manner through a lower midline or Pfannestiel incision. Diathermy
was used only for hemostasis and peritoneal closure was performed.
All patients received 500 mg metronidazole intravenously at the beginning of anaesthesia and operations
were performed under GA with endotrachael intubation in both groups. The bladder was drained with a
Foley catheter in all women. A drain was left from the perineal cavity in both groups.
Surgeon experience: not reported.
First follow up visit was scheduled 4 weeks after the operation and then followed up until complete
recovery.
Duration: March - September 1997 (6 months).
Outcomes Operating time; anaesthetic time; blood loss; haemoglobin change; hospital stay; sick leave and compli-
cations.
Notes
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hwang 2002
Methods Randomisation: sealed envelopes containing computer-generated block randomisation numbers, block
size of 10.
Single centre study, parallel group design with no blinding.
Number of women randomised = 90. No dropouts reported.
Power calculation to estimate sample size performed. Power of analysis was 80% at alpha=0.05
Source of funding: not reported.
Participants 90 women with a mean age of 45.1 years, recruited from ShinKongWuHo-SuMemorial Medical Centre,
Taipei Taiwan.
Inclusion criteria: scheduled for hysterectomy for uterine fibroids; myoma diameter larger than 8 cm
and second myoma less than 5 cm or two myomata, both at least 6 cm in diameter but less than 8 cm
(maximum number of fibroids was three).
Exclusion criteria: indications of adenomyosis; uterine prolapse; chronic pelvic pain; dysfunctional uterine
bleeding; cervical dysplasia; pelvic inflammatory disease.
Interventions AH versus VH versus LH [LH(a)]
AH arm: Abdomen opened by vertical midline or Pfannestiel skin incision. Uterus removed by extrafascial
technique and vaginal cuff closed with continuous interrupted suture followed by reperitonealisation.
VH arm: Patients in Trendelenburg tilt position and given Vasopressin injection. Anterior circumferential
incision of the cervix and posterior V-shape incision. Anterior peritoneal cavity opened and cul-de-sac
of Douglas entered. After uterine artery ligation, volume reducing techniques were performed vaginally.
Peritoneum closed and uterosacral ligaments and vaginal vault sutured.
LH(a) arm: 10 mm trocar inserted into umbilical position, one 5 mm trocar in each lower quadrant
and another inserted suprapubically. Uterosacral ligament incision and round and broad ligaments were
excised. Anterior colpotomy was performed after ligation of the bilateral uterine artery. The rest of the
hysterectomy was completed vaginally. The uterus was removed vaginally by volume reducing techniques
and the vaginal cuff was closed.
All operations performed under general anaesthesia by second author, with the assistance of the other
authors. Standardised postoperative protocol of 2 doses of IV meperidine 50 mg every 4 h for pain control
followed by acetaminophen 325 mg every 6 hours.
Prophylactic antibiotics (cephalosporin 1.0 g every 8 h (three doses/day) combined with aminoglycoside
80 mg every 12 h (two doses/day), for one day were administered to all after surgery.
Follow-up: 6 weeks after surgery.
Duration: June 1999 - May 2001 (2 years).
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Hwang 2002 (Continued)
Outcomes Operating time; hospital stay; intraoperative blood loss; complications; post operation tenderness score;
return to work; antibiotics used.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kunz 1996
Methods Randomisation: method not stated. Single centre study, parallel group design with no blinding.
Number of women randomised = 70, number analysed = 70.
No power calculation for sample size was reported.
Source of funding not reported.
Participants 70 women with a mean age of 43 (LAVH group) and 48 years (AH group), recruited from Stuttgart,
Germany.
Inclusion criteria: scheduled for hysterectomy for non-malignant diseases.
Exclusion criteria: not reported.
Interventions AH versus LH [LAVH].
LAVH arm: A curette is inserted into the uterus and the laparoscopic video camera is introduced. Two 5
mm trocars were inserted. Division of the adnexae from the uterus or the infundibulopelvic ligaments and
round ligaments was accomplished with tissue tension, bipolar coagulation and the use of hook scissors.
Transverse incision on the anterior fold of the broad ligaments bilaterally and transection of the visceral
peritoneum at the bladder resection. Separation of the posterior fold of the broad ligaments, uterine
arteries are skeletonized and demonstrated close to the uterus (2 cm). The hysterectomy was continued
vaginally. The cervix was circumcised and the vaginal skin is reflected. Reflection of the bladder and the
anterior peritoneum is demonstrated. The pouch of Douglas is entered and the sacrouterine ligaments are
clamped and ligated. Uterine arteries are clamped and ligated bilaterally and the uterus extracted vaginally.
The secrouterine ligaments are fixed together and the vagina is closed in interrupted sutures.
AH arm: The abdominal hysterectomies followed a common technique (Ober and Meinrenken 1964).
Both groups received perioperative antibiotic prophylaxis with 2 g of Ceftriaxon, 15 minutes prior to the
operation.
Both groups had a pre and post-operative vaginal ultrasound scan. Pre and post-operative blood tests and
measured CRP post-operatively (day 1 and 3).
Post-operative analgesia was Piritramid (22 mg ampulle), Pentazocin (30 mg ampulle) and Tramadol
hydrochloride (100 mg orally).
Duration: November 1993-February 1995 (1 year and 4 months).
Outcomes Operating time, pain relief, size of uterus, haemoglobin change, stay in hospital and complications.
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Kunz 1996 (Continued)
Notes Paper in German language. Translation was commissioned.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Langebrekke 1996
Methods Randomisation: sealed envelopes containing the assignment prepared by randomisation, using a table of
random digits, numbered 1 to 100.
Multicentre study (n=2), parallel group design with no blinding.
Number of women randomised = 100, number analysed = 100.
No power calculation for sample size was reported.
Source of funding not reported.
Participants 100 women recruited from two hospitals in Norway. The age of the participants was not reported.
Inclusion criteria: women with indications for elective hysterectomy.
Exclusion criteria: proven or suspected malignancies in the pelvic area, suspected intra-abdominal ad-
hesions; uterus enlarged beyond the size of a 12 week size pregnancy; serious cardiopulmonary disease;
previous colporrhapy.
Interventions AH versus LH [LH(a)].
LH(a) arm: A 10-mm laparoscope was inserted through the umbilicus and a general inspection of the
entire pelvic cavity was performed. Two 5 mm trocars were introduced into the iliac fossae. A 12 mm
trocar was placed in the midline 4 cms below the umbilicus in cases where the automatic stapler endo-
GIA was used. Bipolar diathermy or GIA were used to divide the ligaments. With unipolar scissors, the
vesicouterine perioneal fold was cut and the bladder mobilized. The uterine arteries were coagulated with
bipolar diathermy. The vagina was opened laparoscopically with unipolar scissors and the uterus removed
vaginally. The vagina was closed with resorbable sutures from below, the sutures including the cardinal
ligaments. All operations performed exclusively by two of the authors.
AH arm: according to standard techniques. Abdomen was entered via a Pfannenstiehl incision. The entire
abdominal cavity was palpated and the pelvis inspected. The uterine ligaments were clamped and ligated.
The bladder peritoneum was opened and the bladder was mobilized away from the cervix and upper
anterior vaginal wall. Uterine vessels were clamped, cut and ligated. The vagina was closed with resorbable
sutures. Performed by any skilled gynaecologist in the department.
Cephalosporine (2 g IV) and low molecular heparin (injected subcutaneously) was given to both groups
postoperatively.
Follow up: until participants returned to work/normal activities.
Duration: not reported.
Outcomes Operation time; hospital stay; time elapsed before resuming work; postoperative pain; complications and
blood loss.
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Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Long 2001
Methods Randomisation: randomly assigned to treatment groups. Method not stated and allocation concealment
not reported.
Single centre study, parallel group design with no blinding.
Number of women randomised = 167
Number of dropouts = 13
Number of women analysed = 101 (participants excluded if hysterectomy performed for reasons other
than uterine fibroids of adenomyosis).
No power calculation for sample size or intention to treat analysis was reported.
Source of funding: not reported.
Participants 101 women with a mean age of 46.3 (LAVH group) and 45.8 (LH(a) group) recruited from Kaohsiung
Municipal Hsiao Kang Hospital, Taiwan.
Inclusion criteria: indications of uterine fibroids of adenomyosis and contraindications for VH - uterine
weight >280 g, previous pelvic surgery, history of PID, need for adnexectomy, lack of uterine descent and
limited vaginal access.
Criteria for choosing laparoscopic hysterectomy was based on the uterine volume, less than that of a 16
weeks pregnancy (700 g).
Exclusion criteria: suitable for a vaginal hysterectomy and the uterine volume was greater than a 16 week
pregnancy.
Interventions LAVH versus LH(a) [a comparison of two LH techniques].
LAVH arm: If the ovaries were to be conserved, the Fallopian tubes, round and utero-ovarian ligament was
resected with bipolar forceps and scissors. For adnexectomy, mesosalpinx, round and infundibulopelvic
ligament were resected. Laparoscopic dissection of the bladder flap, resection of the broad ligaments,
anterior and posterior colpotomies were performed. Proceeded vaginally - clamping, transecting and suture
ligating of uterine vessels, cardinal and uterosacral ligaments. Closure of peritoneum and vaginal vault
anchored to the cardinal-uterosacral ligament complex after removing uterus.
LH(a) arm: Same manner as the LAVH procedure above the uterine artery level. After dissection of the
bladder flap and resection of the broad ligament, the uterine artery was coagulated by bipolar electroco-
agulator and separated from the uterine sidewall by scissors. Bilateral dessication and transection of the
cardinal-uterosacral ligament complex. Circular colpotomy was performed close to the cervix and uterus
was removed through the vagina.
All operations performed under GA and by the same gynaecologist for each procedure (LAVH by one
surgeon and LH(a) by another).
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Long 2001 (Continued)
Post-operative analgesia included lysine aspirin which was administered intravenously. Antibiotic prophy-
laxis IV cefazolin 1 g administered pre- and post-operatively.
Follow-up: until discharged from hospital.
Duration: November 1999 - December 2000 (1 year and 1 month).
Outcomes Operation time, blood loss, hospital stay, cost, complications and sexual symptoms.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lumsden 2000
Methods Randomisation: performed by the research nurse using a computer-generated schedule.
Multicentre (n=3) study, parallel group design with no blinding.
Number of women randomised = 200, number analysed = 190. 7 did not attend for operation and the
case records were not available for a further 3 women.
Power calculation to estimate sample size performed. 120 patients per arm allowed an 80% chance of
detecting a 15% difference in complication rates at a 5% level using a two-sided test.
Analysis was stated as by intention to treat, but not all randomised participants were analysed.
Source of funding: Scottish Home and Health Department, Scotland.
Participants 190 women with a mean age of 42.7 years (AH group) and 41.1 (LH group), recruited from three hospitals
in Glasgow, Scotland.
Inclusion criteria: scheduled for AH for benign gynaecological disease and they were not suitable for VH
because of a uterine size in excess of 14 weeks or a requirement for oophorectomy.
Exclusion criteria: suitable for VH.
Interventions AH versus LH. Operation procedures not reported. Performed by 5 consultant gynaecologists who have
undertaken a minimum of 50 LH procedures.
Follow up: participants asked to keep a diary of recovery ’milestones’ and reviewed by the research nurse
four weeks after surgery. Euroqol Health Questionnaire completed at one, six and twelve months after
surgery.
Duration: 2 years
Outcomes Length of operation; length of hospital stay; admission to ITU; readmissions; women requiring additional
surgery; blood transfusions; complications (major and minor); patient reported outcomes; costs and
change in health status.
Notes
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Marana 1999
Methods Randomisation: computer generated sequence. Multicentre study (n=4), parallel group design with no
blinding.
Number of women randomised 116, number analysed 116.
Power calculation performed for sample size, the sample size was selected to detect a difference of 25% in
total complication rates with a power of 80% at the 5% level of significance, given a complication rate in
the control group of 42%. No drop-outs.
Source of funding not reported.
Participants 116 women with a mean age of 49 years, recruited from 4 Italian university hospitals.
Inclusion criteria: scheduled for AH for benign disease and had one or more of the following contraindica-
tions to VH: uterine size >280 g and an upper limit of 16 weeks gestation (700 g); previous pelvic surgery;
history of pelvic inflammatory disease; moderate or severe endometriosis; concomitant adnexal mass or
indication for adnexectomy; and nulliparity with lack of uterine descent and limited vaginal access.
Exclusion criteria: suitable for VH.
Interventions AH versus LH [LAVH].
LAVH arm: 10-mm laparoscope introduced through the umbilicus, and 3 accessory 5mm reusable trocars
were introduced suprapubically. The pelvis and upper abdomen were then accurately evaluated, and
endometriotic lesions, adhesions, or ovarian cysts, when present, were treated appropriately. When the
ovaries were to be conserved, bipolar forceps and scissors were used to resect the round and uteroovarian
ligaments with the fallopian tubes.
For adnexectomy, bipolar forceps and scissors were used to resect the round and infundibulopelvic lig-
aments, mesosalpinx, and mesovarium. Opening of the bladder flap was performed at the laparoscopic
phase, whereas bladder dissection was performed during the vaginal phase. Laparoscopic hemostasis was
achieved using exclusively bipolar electrocoagulation.
The vaginal phase included circular incision of the vagina; bladder dissection to the laparoscopically
opened bladder flap; entry in the posterior cul-de-sac; and clamping, transecting, and suture ligating of
uterosacral ligaments, base of cardinal ligaments, and uterine vessels.Where necessary, wedgemorcellation,
coring, or bivalving was performed. Peritoneal closure with pedicles exteriorized and closure of vaginal
vault anchored to the uterosacral and cardinal ligaments concluded the vaginal phase.
AH arm: Performed according to the technique described by Mattingly and Thompson.
Surgeon experience: not reported.
Pre-operative evaluation of uterine size, mobility and pelvic sonogram. Haemoglobin and hematocrit
determinants performed for autologous blood transfusion, performed if HB level > 11 g/100 mL.
All received antibiotic prophylaxis (intravenous piperacillin 2 g) administered 30 mins before surgery.
Postoperative medication consisted of the administration of ketorolac by intramuscular injection or by
mouth every 6 hours for the first 24 hours.
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Marana 1999 (Continued)
Post-operative follow-up included evaluation of pain on post-operative days 1, 2 and 3, length of post-
operative hospital stay and evaluationof post-operative complications.Duration: until patient left hospital.
Duration: October 1995 - November 1996 (1 year, 1 month)
Outcomes Blood loss; postoperative fever; postoperative pain; length of postoperative hospital stay; postoperative
complications; hemoglobin reduction and intraoperative conversion to abdominal surgery.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Miskry 2003
Methods Randomisation: computer generated in blocks of 10; sequentially numbered sealed opaque envelopes,
opened by nursing staff immediately prior to surgery.
Double blind until discharge from hospital, maintained by a sham opaque lower abdominal dressing
(unless pyrexia or other complication necessitated direct inspection of the abdomen) and vaginal staining
with methylene blue in cases undergoing VH.
Two centre study, parallel group design.
Number of women randomised = 36, number analysed = 36.
Power calculation performed and adhered to: 36women required for 80%power to show a 2-day difference
in hospital stay at p=0.05.
Source of funding: not stated.
Participants 36 women with mean age 42 years, recruited from Royal Free and North Middlesex Hospitals, UK.
Inclusion criteria: scheduled for elective hysterectomy.
Exclusion criteria: genital tract malignancy; adnexal pathology; uterine size >14 weeks; need for concurrent
procedure (eg vaginal repair, colposuspension); reduced uterine mobility on VE; inadequate vaginal access.
Interventions AH versus VH.
Total hysterectomy performed by standard technique for each route. Low transverse incision, closed with
subcuticular absorbable suture, for AH; Heaney technique for VH. In all cases, concurrent oophorectomy
performed if indicated; peritoneal and vaginal vault closed.
Performed by most senior surgeon available.
All GA plus caudal block for one VH case.
Antibiotic prophylaxis Co-amoxivlav 1.2 g at induction of anaesthesia. Thromboprophylaxis heparin
5000 units at induction and twice daily until mobile.
Follow-up at 6 weeks and 6 months with completion of SF-6 Short Form General Health Survey.
Duration of trial not stated.
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Outcomes Primary outcome: duration of hospital stay.
Secondary outcomes: analgesic requirements; complications; return to normal function.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Olsson 1996
Methods Randomisation: sealed opaque envelopes. 1:1 ratio.
Single centre, parallel group design with no blinding.
Number of women randomised = 143, number analysed = 143.
Power calculation for sample size was performed, assuming a complication probability of 40% for AH,
the power of predicting a difference in complication rate was at least 80% at the 5% level, two-sided test,
provided that the probability of complications following LH(a) is at most 18% and at least 64% when 70
patients are included in each group.
Source of funding: Goteborg Medical Society Fund, Swedish Medical Research Council.
Participants 143 women with median age 48 years, recruited from Sahlgrenska University Hospital, Sweden.
Inclusion criteria: scheduled for AH for benign disorders, with a maximum uterine width of less than 11
cm and not considered suitable for VH.
Exclusion criteria: suitable for VH (adnexa are not to be removed; no suspicion of endometriosis or post-
inflammatory disorders, when uterine size is normal, or in the case of uterovaginal prolapse, less than the
size of an eight week pregnancy).
Interventions AH versus LH [LH(a)].
LH(a) arm: All patients were prescribed a second generation cephalosporin as well as metronidazole
intravenously during the operation and by oral administration for 2 days after surgery. Ureters were
identified, where this was difficult, the ureters were dissected free down to the level of the uterine arteries.
If the adnexa were to be removed, the infundibulopelvic ligaments were transected by diathermial cautery
and monopolar scissors. If the adnexa were to be conserved the utero-ovarian pedicles were transected on
both sides, using the same instruments. The round ligaments and the upper portion of the broad ligaments
were divided using monopolar scissors and the bladder was dissected to the level just below the vaginal
cuff. The posterior part of the broad ligaments were divided by scissors close to the uterus, down to the
upper part of the uterosacral ligaments, which were then transected. The uterine arteries were transected
close to the uterus after bipolar coagulation. The upper portion of the cardinal ligaments were divided
close to the uterus, after which an incision was made into the anterior fornix of the vagina. The vaginal
phase: vaginal epithelium surrounding the cervix was transected as well as any residual tissue from the
cardinal and uterosacral ligaments. The transected ligaments were ligated together and incorporated into
the vaginal wall. 2 out of 5 surgeons of senior registrar grade and specifically trained in LH(a).
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Olsson 1996 (Continued)
AH arm: Antibiotics were not routinely prescribed in this group of patients. They underwent either a
lower midline or Pfannenstiel incision. If the adnexa were to be removed, the infundibulopelvic ligaments
were clamped, transected and ligated. In cases where the adnexa were not to be removed, the utero-ovarian
pedicles were transected and ligated. The anterior broad ligaments were divided down to the vesico-vaginal
junction and the bladder reflected to just below the vaginal cuff. The uterine vessels were divided close
to the uterus. Following division of the cardinal and uterosacral ligaments, the uterus was excised. The
vaginal cuff was closed with interrupted sutures and the peritoneal layers closed and attached to the top
of vagina. Two out of 10 surgeons of senior registrar grade trained in AH.
Follow up: 4-6 weeks after surgery, all patients returned for a gynaecological examination including vaginal
ultrasound. 6-8 weeks after surgery patients were asked to complete an anonymous questionnaire if they
considered the duration of their post-operative hospital stay and sick leave to have been adequate. In a
subgroup of patients (TLH: n=38; AH: n=38), postoperative health status and QOL were self assessed
prospectively 1, 3, and 12 weeks after surgery using “The Medical Outcome Trust 36-item Short-Form
Health Survey questionnaire”.
Duration: not reported.
Outcomes Operating time (mins); complications; postoperative pain relief; convalescence (sick leave); hospital stay;
QOL; economic analysis (cost)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Ottosen 2000
Methods Randomisation: computer generated numbers and information on the allocation schedule was kept in
sealed opaque envelopes prepared by and successively opened by the research nurse.
Single centre study, parallel group design with no blinding.
Number of women randomised = 120, number analysed = 120. Randomly allocated to one of three
operating methods in four blocks of 30 to ensure a balanced number of patients throughout study period.
Interim analysis done after 25 patients were randomised to each group.
Power calculation for sample size performed, sample size based on reported hospital stay for vaginal and
abdominal hysterectomy of 2.3 and 4 days, respectively. If 1.5 is the SD for hospital stay, 40 women were
randomised to achieve a power of 80% at alpha = 0.05.
Source of funding: Thelma Zoegas Foundation and the Stig and Ragna Gorthons Foundation, Sweden.
Participants 120 women with mean age 47 years (AH group), 49 years (VH group) and 48 years (LAVH group),
recruited from the Hospital of Helsingborg, Sweden.
Inclusion criteria: scheduled for hysterectomy for anticipated benign causes. Inclusion: menorrhagia,
leiomyomas <15 cm in diameter, dysplasia, endometrial atypia and pain.
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Exclusion criteria: ovarian pathology, uterus larger than 16 weeks of gestational size, previously known
dense adhesions, narrow vagina or obvious inaccessible uterus.
Interventions AH versus VH versus LH [LAVH] - three treatment arms.
LAVH arm: the laparoscopic part was minimised. Trocars were left in place and after closing the vaginal
wall the surgeon returned to laparoscopic view to confirm haemostasis. The surgery was performed under
GA in 109/120 cases, spinal block in 3/120 or in combination with epidural block in 8/120 cases.
AH arm: the abdomen was opened and closed in different ways according to surgeon preference. The
uterus was removed by extrafascial technique and the vagina closed and covered by peritoneum.
VH arm: the vault was injected with 20 mL of mepivacain/adrenalin before incision in order to minimise
bleeding. The peritoneal folds were opened and ligaments and uterine vessels were divided. If at this
time the uterine size did not allow easy exteriorisation, bisecting, coring, morcellation, enucleation or
combinations of these volume-reducing techniques were performed. The peritoneum was closed, followed
by suturing of the sacrouterine ligaments and vaginal vault.
One of 15 gynaecological surgeons, experience varied and in some cases residents performed under su-
pervision.
All patients had at least one dose of prophylactic antibiotic perioperatively, namely cefuroxim 1.5 g
intravenously and metronidazol 1g rectally. A daily dose of exoxaparin 20 mg subcutaneously was given
as thrombolic prophylaxis through the hospital stay.
Followup: 2weeks post operation in outpatient clinic for examination to detect complications and evaluate
need for further sick leave.
Duration: January 1996 - May 1998 (2 years, 5 months).
Outcomes Duration of surgery, duration of anaesthesia, stay in hospital, recovery time, peroperative blood loss and
complications.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Perino 1999
Methods Randomisation: method not stated and allocation concealment not reported.
Single centre study, parallel group design with no blinding.
Number of women randomised = 102, number analysed = 102.
No power calculation for sample size was reported but there were no reported dropouts.
Source of funding: not reported.
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Participants 102 women with a mean age of 48 years, recruited fromGynaecologic University Hospital, Palermo Italy.
Inclusion criteria: Scheduled for hysterectomy for benign diseases.
Exclusion criteria: not stated.
Interventions AH versus LH [TLH].
TLH arm: After a CO2 pheumoperitoneum was created, a 10 mm trocar was placed in the umbilical
site to introduce the laparoscope and the camera. Three ancillary 5 m trocars were placed suprapubically.
After an abdominal inspection, lysis of any adhesions was performed, the uterus was then mobilized. After
bipolar coagulation, the round ligament was sectioned at 3 cm from the uterus. The areolar tissue of the
broad ligament was then dissected and its posterior fold fenestrated at an avascular area above the uterine
vessels. The infundibulo-pelvic ligament vessels were coagulated and cut using bipolar forceps and scissors
under direct visualization of the pelvic ureter. Once the uterine ligaments were sectioned, the operation
continued centrally in a downward direction. If the adnexae were not to be removed, the utero-ovarian
ligament was coagulated and sectioned proximal to the ovaries. The vesico-uterine peritoneal fold was
opened by scissors and a bladder dissection from the low uterine segment down to the upper part of the
vagina was performed. The utero-sacral ligaments were then coagulated and sectioned. The uterine artery
was skeletonized and then coagulated with bipolar forceps and cut with scissors. Incision and coagulation
of the cardinal ligaments to expose the vaginal fornices, separated from the stump of the uterine artery.
Circular colpotomy was then performed and the uterus was removed from the vagina. The vaginal vault
was then sutured laparoscopically or vaginally.
AH arm: Performed according to the technique described for benign disease (Mattingly and Thompson).
All operations performed by the same team of three surgeons with experience of 100+ TLH procedures.
Follow up: until participants were discharged from hospital. Postoperative pain was assessed 3 days after
surgery.
Duration: January 1997 - 30 September 1998 (1 year, 9 months).
Outcomes Operating time; blood loss; postoperative pain; postoperative decrease in haemoglobin; complications and
duration of postoperative hospital stay
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Raju 1994
Methods Randomisation: sealed envelopes containing computer generated block randomisation numbers. Block
size of 10.
Single centre study, parallel group design with no blinding.
Number of women randomised = 80, number analysed = 80.
Power calculation for sample size performed, 40 patients in each arm were estimated to detect a 25%
difference in morbidity between the groups, with a power of 90% at the 5% level.
No dropouts were reported.
Source of funding: not reported.
Participants 80 women with mean age of 46 years, recruited from St Thomas’s Hospital, London.
Inclusion criteria: scheduled for hysterectomy and bilateral oophorectomy for benign conditions.
Exclusion criteria: morbid obesity, uterus larger than 14 weeks gestation size, or uterovaginal prolapse.
Interventions AH + BSO versus LH [LAVH] + BSO.
LAVH+BSO arm: 5.5 mm flap-valved trocars were inserted enabling the insertion of laparoscopic instru-
ments. 12 mm trocar and cannula were introduced suprapubically in the midline 3 cm above the upper
border of the symphysis pubis as a port for the use of the Autosuture Multifire Endo GIA 30 stapling
device.The cervix was grasped with a vulsellum and a broad-ended blunt uterine curette was inserted to
manipulate the uterus from the perineal end. Any adhesions between the uterus or adnexae to adjacent
structures were divided with scissors after diathermy coagulation. Both round ligaments were treated with
diathermy and cut with scissors approx 3 cm from the internal inguinal ring whilst holding the ligament
with a grasping forceps. The peritoneum of the anterior leaf of the broad ligament was dissected from
the divided round ligament back towards the infundibulo-pelvic ligament thus opening the tissue space
between the two folds of broad ligament. The posterior leaf of the broad ligament was then pierced with
endoshears to make a window, a safe distance above the ureter which had been previously identified. The
ovarian pedicle was then sized for thickness of tissue by means of a GIA endogauge inserted through the
midline suprapubic incision. The correct size of endostapling clamp was selected. The ovarian pedicle
was clamped and cut with the appropriate GIA endostapling device, placed from the upper border of the
infundibulo-pelvic ligament and with the jaws of the stapler passing well through the peritoneal window
in the broad ligament. By using this technique each ovarian pedicle required only one firing of the GIA
stapler to divide it. Finally the uterovesical fold of the peritoneum was divided with scissors and sometimes
the uterosacral ligaments were divided after diathermy coagulation.
The uterus, tubes and both ovaries were then removed vaginally after circumcising the cervix and opening
the pouch of Douglas to allow ligation and division of the cardinal ligaments and uterine vessels as in
a traditional vaginal hysterectomy. The vaginal vault was anchored to the cardinal ligaments and closed
with interrupted sutures.
Operations performed on by one of the authors.
AH+BSO arm: Procedures were performed using a standard technique.
Operations performed by one of the authors or by another surgeon of senior registrar grade.
Premedication: temazepam20mg, 2hours before operation.GA inducedwith thiopentone andmaintained
with enflurane and nitrous oxide. Under anaesthesia a bolus intravenous injection of Augmentin, 1.2g
was given. Antibiotic therapy continued for 7 days postoperatively
Follow up: 6 weeks after surgery and until participants return to work.
Duration: March 1992 - October 1993 (1 year, 8 months)
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Outcomes Operating time, blood loss, haemoglobin change, hospital stay, post-operative analgesia, complications,
recovery time (subjective assessment of patient’s general wellbeing and return to normal activity) and cost.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Ribiero 2003
Methods Randomisation: method not stated.
Single centre study, parallel group design with no blinding specified.
Number of women randomised = 60, number analysed = 60.
No power calculation for sample size reported.
No dropouts reported.
Source of funding: Foundation of Research Support from Sao Paulo State.
Participants 60 women with overall mean age 42.3 years (range 34 - 76 years). Participants were recruited from Sao
Paulo University School of Medicine Hospital, Brazil.
Inclusion criteria: Benign uterine disease: myoma n=41; adenomyosis n=19.
Exclusion criteria: uterine volume greater than 400 mls; use of any anti-inflammatory medication during
preceding 3 months; diabetes mellitus; coagulation disorders; autoimmune diseases.
Interventions AH versus VH versus LH [TLH].
AH by Thompson and Warshaw technique. VH by Heaney’s technique. LH [TLH]: 10mm laparoscope
inserted at umbilicus, two 5mm secondary ports for laparoscopic instruments. Uterine mobiliser with
blunt tip used to antevert uterus and delineate vaginal fornices. Round ligaments divided with monopolar
forceps and vesico-uterine fold divided with scissors and bladdermobilised until anterior vagina identified.
Utero-ovarian ligament and fallopian tube pedicles dessicated with bipolar forceps, then scissors division
of broad ligament peritoneum. Uterine artery grasped, elevated and bipolar coagulated. Cardinal and
uterosacxral ligaments divided with monopolar forceps. Vagina entered posteriorly near cervico-vaginal
junction. 4 cm vaginal delineator outlined circumferentially the cervico-vaginal junction and prevented
loss of pneumoperitoneum.Monopolar forceps completed the circumferential culdotomy.Uterus removed
vaginally (after morcellation if necessary). Laparoscopic vaginal vault interrupted suturing and suspended
by suture attachment to uterosacral/cardinal pedicles, sutures being tied extracorporally.
Surgeon experience: not reported.
Follow up: routinely up to 6 days.
Antibiotic and thromboprophylaxis not specified.
Duration: not reported.
Outcomes Operative time; pre- and post-operative haemoglobin; complications.
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Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Richardson 1995
Methods Randomisation: random numbers table.
Single centre study, parallel group design with no blinding.
Number of women randomised = 45, number analysed = 45.
No power calculation for sample size reported.
No dropouts reported.
Source of funding: not reported.
Participants 45 women with mean age of 41 years (LH group) and 45 years (VH group). Participants were recruited
from Royal Free Hosptial, London.
Inclusion criteria: contraindications for vaginal surgery according to traditional criteria (absence of vaginal
prolapse, nulliparity, uterine enlargement, previous pelvic surgery endometriosis and need for oophorec-
tomy).
Exclusion criteria: uterine size greater than the equivalent of 16 weeks’ gestation, endometrial carcinoma,
adnexal masses, known dense pelvic adhestions, or moderate/severe endometriosis.
Interventions VH versus LH.
LH arm: The laparoscope was inserted sub-umbilical incision, and usually two 5mm secondary portals
were used for the laparoscopic instruments. Surgery was performed under the guidance of the image
generated by a Supercam 9050 PB video chip camera attached to a 30 degree forward oblique laparoscope.
The principal method of haemostasis was bipolar electrosurgical dessication but Endo-GIA 30 linear
staplers were used in 8 women. In 1 woman VH was done after diagnostic laparoscopy (stage 0 VH) and
in 2 VH was carried out after laparoscopic adhesiolysis had made this possible (stage 1 LH). When the
ovaries were conserved, bipolar diathermy was used medially to dessicate the round and ovarian ligaments,
and the fallopian tube. The approach to the ovarian pedicle during oophorectomy depended on whether
the uterine vessels were to be divided laparoscopically or vaginally. If divided vaginally, the ovarian vessels
were coagulated and divided but not the round ligaments. Dissection then proceeded towards the uterine
origin of the round ligament, after which the hysterectomy was completed vaginally (stage 2 LH) or after
laparoscopic mobilisation of the bladder (stage 3 LH). If the uterine vessels were treated laparoscopically
(stage 4 LH), the round ligaments were always divided, together with the ovarian vessels and fallopian
tubes, and the dissection continued to the level of the uterine arteries which were then dessicated and
cut close to the uterus. Laparoscopic dissection only continued further than the uterine artery in 3 cases
(stage 5 LH), all other procedures being completed vaginally.
VH arm: Modified Heaney approach.
Surgeon experience: not reported.
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Follow up: 6-8 weeks after surgery, participants completed a questionnaire on their recovery. All kept a
prospective diary of their recovery for 6 weeks.
Duration: not reported.
Outcomes Operating time; analgesia required; hospital stay; recovery time and postoperative complications.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Schutz 2002
Methods Randomisation: computer-generated randomisation list and concealment by telephone inquiry.
Single centre study, parallel group design with no blinding.
Numer of women randomised = 48, number analysed = 48.
Power calculation to estimate sample size performed. No reported dropouts.
Source of funding: not reported.
Participants 48 women with median age of 48 years, recruited from Friedrich Schiller University, Jena Germany.
Inclusion criteria: sonographically estimated uterine weight >200g and patient has no preference for either
surgical technique.
Exclusion criteria: not stated.
Interventions AH versus LH [LH(a)].
LH(a) arm: Either type I or II procedure. Type I: the laparoscopic part included coagulation and transection
of the round ligament and transection of the bladder peritoneum. If the adnexae was desired, the fallopian
tube and the ovarian ligamentwere coagulated and transected.Where salpingo-oophorectomywas needed,
the infundibulo-pelvic ligament was isolated, coagulated and transected following visualisation of the
ureter. Type II: the uterine artery was identified at its origin when branching off the internal iliac artery.
The identification was made coming from either the internal umbilical ligament or the pararectal fossa.
Prior to coagulation of the uterine artery, the ureter was identified and pushed medially. After coagulation,
it was left to the discretion of the surgeon to transect the uterine artery. The uterus was mobilized by
pulling on the transected round ligaments and no intrauterine probes were applied for mobilization of
the uterus.
71.4% operations performed by attending physician, 28.6% by resident assisted by physician.
AH arm: followed the standard extrafascial technique. A Balfour retractor was used and the skin incision
was stapled.
40% performed by physician and 60% by resident assited by physician.
Follow up: following discharge from hospital the participants received a self-administered questionnaire
to evaluate their recouperation over a period of 12 months.
Duration: August 1995 - December 1997 (2 years, 4 months).
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Outcomes Primary outcome: length of stay in hospital. Secondary outcomes: Operating time; postoperative pain;
blood loss and recovery time until return to full work activity.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Seracchioli 2002
Methods Randomisation: computer generated randomisation unknown to the surgeons.
Single centre study, parallel group design with no blinding.
Number of women randomised = 122, no dropouts reported.
No power calculation for sample size was reported.
Source of funding: not reported.
Participants 122 women with a mean age of 46.3 (LH(a) group) and 47.3 (AH group), recruited from S. Orsola
Hospital, University of Bologna Italy.
Inclusion criteria: eligible for AH due to a large uterus (>14 weeks) caused by myomas. Uterine weight
>300g, determined by a pelvic examination and transvaginal ultrasonography.
Exclusion criteria: uterus projecting above the transverse umbilical line and with other pelvic pathologies
(prolapse, pelvic floor relaxation, stress incontinence and adnexal masses). Medical conditions that re-
quire hospital monitoring, eg. diabetes, heart disease, if they had undergone previous abdominal surgery
requiring longitudinal laparotomy or contraindications to operative laparoscopy.
Interventions AH versus LH [LH(a)]
LH(a) arm: 10 mm cannula placed in the umbilical site to introduce the lapaproscope and camera. Two
5mm suprapubic access routes were inserted lateral to deep inferior epigastric arteries. A third cannula
was inserted between the umbilicus and xiphoid. Round ligaments, fallopian tubes, and utero-ovarian
ligaments(or infundibulopelvic ligaments if the ovaries were to be removed) were coagulated and sectioned.
Uterine peritoneal fold was opened with scissors, dissecting the bladder off the lower uterine segment
and cervix. Incision of the fornix, extended laterally, stopping close to uterine vessels. Uterine pedicles
skeletonised, coagulated and sectioned. Parametrial tissues were coagulated and sectioned so the uterus is
free to be removed vaginally. Vaginal vault was sutured vaginally with the cardinal-uterosacral ligaments.
Antibiotic prophylaxis of ampicillin 2 g.
All surgical procedures were performed by the same investigators under GA.
Follow-up:Phone interviews 2 months after discharge to determine the number of days before going back
to normal activities.
Duration: January 1997- January 2001 (3 years).
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Outcomes Operating time, laparoconversions, blood loss, haemoglobin drop, fever, transfusions, hospital stay and
convalescence.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Soriano 2001
Methods Randomisation: pre-determined computer-generated randomization code.
Single centre study, parallel group design with no blinding.
Number of women randomised = 80, number analysed = 80.
Power calculation to estimate sample size performed. Assumed that the incidence of complications in
patients undergoing LH(a) is 10% and there will be an increase of complication rate to 40%, with alpha
(type I error) of 0.05 and beta (type II error) of 0.2. It was planned to recruit at least 35 women to each
arm.
No reported dropouts.
Source of funding not reported.
Participants 80 women with a mean age of 49 years, recruited from the Hopital Hotel-Dieu, Paris France.
Inclusion criteria: women referred for hysterectomy due to benign pathology. Uterine size larger than
280g and one or more of the following: previous pelvic surgey, history of pelvic inflammatory disease,
moderate or severe endometriosis, concomitant adnexal masses, or indication for adnexectomy.
Exclusion criteria: suspicious adnexal mass, anesthetic contra-indications for laparoscopic surgery.Women
with contra-indications to acetaminophen, or to nonsteroidal antiinflammatory drugs and those whose
pain evaluation was judged unreliable due to neurological disease, or treatment by steroids, NSAIDs or
opoids prior to surgery.
Interventions VH versus LH [LH(a)].
LH(a) arm (LH type IV): After induction of pneumoperitoneum and insertion of the video laparoscope,
three suprapubic trocars were introduced for the ancillary instruments. The pelvis and the upper abdomen
were evaluated and endometric lesions, adhesion or ovarian cysts, when present were treated. When the
ovaries were to be conserved, bipolar forceps and scissors were used to resect the round ligament and
the uteroovarian ligaments with the fallopian tubes. For adnexectomy, bipolar forceps and scissors were
used to resect the round and infundibulopelvic ligaments, mesosalpinx and mesovarium. The laparoscopy
included opening the bladder flap and bladder dissection, coagulating and transecting the uterosacral
ligaments, base of cardinal ligaments and uterine vessels. Laparoscopic hemostasis was achieved using
exclusively bipolar electrocoagulation. The vaginal phases included only circular incision of the vagina
and wedge morcellation, coring or bivalving was performed. Peritoneal closure and closure of the vaginal
vault concluded the vaginal phase.
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VH arm - performed using the modified Heaney procedure. When necessary, wedge morcellation, coring,
or bivalving was performed.
Surgeon experience: not reported.
Prophylactic antibiotic (cefazoline 2 g IV and low molecular heparin the evening before the operation.
Follow up: until participants were discharged from hospital.
Duration: January 1999 - December 1999 (1 year).
Outcomes Uterine weight; operative time; hemoglobin drop; postoperative complications; blood loss; pain relief and
hospital stay.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Summitt 1992
Methods Randomisation: computer generated randomisation numbers.
Single centre study, parallel group design with no blinding.
Number of women randomised = 56, number analysed = 56. One operation was unsuccessful therefore
for certain outcomes only 55 were analysed.
No power calculation for sample size was reported.
Analysis by intention to treat.
Source of funding: not reported.
Participants 56 women with a mean age of 38 years, recruited from a gynecology clinic, University of Tennessee,
Memphis USA.
Inclusion criteria: 1) age 18-65 years; 2) no significant medical illness that required prolonged post-
operative monitoring or care; 3) a telephone in working order; 4) a support person who could assist the
patient for the first 48 hours after surgery and 5) an understanding of all post-operative instructions.
Criteria for VH: 1) uterine size no larger than 16 gestational weeks; 2) the prescence of uterine mobility; 3)
a pubic arch of at least 90 degrees. Factors that did not influence the decision to proceed vaginally include:
1) a preoperative diagnosis of pelvic pain; 2) the need for oophorectomy, or 3) a history of previous pelvic
surgery.
Exclusion criteria: 1) A concomitant anterior or posterior colporrhaphywas required; 2) cervical conization
was performed within the previous 48 hours; and 3) additional antibiotic prophylaxis was required for
valvular heart disease. They were also excluded if they had absolute contraindications to laparoscopy, such
as 1) any condition that could not tolerate anaesthesia, 2) severe bleeding disorder, 3) acute peritonitis of
the upper abdomen and uterine myomata or 4) a pelvic mass larger than 16 gestational weeks in size.
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Interventions VH versus LH [LH(a)].
LH(a) arm: Three 12-mm trocars were used, one placed infraumbilically and one placed in each lower
quadrant approx. 6-8cm above the pubic rami, lateral to the inferior epigastric arteries. AHulka tenaculum
was used to manipulate the uterus. The bladder flap was developed by incising the vesicouterine fold of
peritoneum and dissecting the bladder below the cervix. The urethers were then identified and mobilized
using linear incisions in the medial leaf of the broad ligament, midway between the uterosacral ligaments
and infundibulopelvic vessels.
The Multifire EndoGIA disposable surgical stapler was used to staple-ligate and cut all uterine pedicles,
each consisting of the round ligament, fallopian tubes, and utero-ovarian ligament, were cut. If the
ovaries were to be removed, the stapler was instead placed outside the tube and ovary, encompassing the
infundibulopelvic ligament. The uterine arteries were next staple-ligated and cut bilaterally. If possible,
the stapling device was also used to ligate and cut the cardinal ligaments. Otherwise, stapling of uterine
pedicles ended and the anterior vaginal formix was enteredwith unipolar cautery, incising over amoistened
sponge distending the anterior vagina. The remainder of the hysterectomy was completed vaginally.
Performed by a team of 3 surgeons (2 attending faculty and a senior gynaecology resident).
VH arm: Anesthesiologist’s choice of general or regional anesthesia. A modified Heaney technique was
performed using O-coated polyglycolic acid suture for all pedicles. The vaginal cuff was closed in all cases.
Performed by a gynaecology resident with attending faculty member.
All received pre-operative antibiotic prophylaxis (cefazolin 2 g ) intravenously. If allergic to penicillin, 200
mg dose of doxycycline intravenously was used.
Post-operative follow-up consisted of a telephone call by the attending surgeon on the evening of surgery
and the first 2 post-operative days. Patients were then seen 1 and 6 weeks post-operatively in the outpatient
clinic.
Duration: June 1991 - February 1992 (9 months).
Outcomes Operating time, blood loss, anaesthesia time, intraoperative complications, febrile morbidity, pain relief
and costs.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Summitt 1998
Methods Randomisation: computer-generated randomisation list. Each surgical assignment placed in consectutive
sealed envelopes and opened by an independent person (study secretary).
Multicentre study (n=3), parallel group design with no blinding.
Number of women randomised = 67, number analysed = 65. 2 women who were randomised refused
their assigned procedure and they were removed from the study and their random numbers discarded.
Power calculation to estimate sample size was not reported.
Analysis said to be by intention to treat, but 2 randomised participants were not analysed.
Source of funding: US Surgical Corporation, Norwalk, Connecticut USA.
Participants 65 women with a mean age of 38.3 (LH(a) group) and 41.5 (AH group), recruited from three hospitals
in the USA.
Inclusion criteria: Scheduled for AH for benign diseases. Indications for AH: 1) documented visual
diagnosis of pelvic endometriosis; 2) documented pelvic adhesions; 3) three ormore previous laparotomies;
4) uterine leimyomata 12-18 gestational weeks in size; 5) previous tuboovarian abcess or two documented
episodes of pelvic inflammatory disease requiring IV antibiotic therapy; 6) adnexal mass in the prescence
of an indication for hysterectomy; and 7) indicated hysterectomy with lack of mobility and unfavorable
vaginal introitus. The following inclusion criteria were met: 1) age at least 18 years, 2) a working telephone
in the home, 3) an available support person in the home for 48 hours after surgery, and 4) an understanding
of the postoperative instructions.
Exclusion criteria: concomitant colporrhaphy, urethropexy, vaginal vault suspension, or a nongynecologic
major operation required. Medical conditions requiring in-hospital monitoring or if they had known
cervical or endometrial cancer. Candidates were also excluded if they had absolute contraindications
to operative laparoscopy, including: 1) uterine leiomyomas or pelvic masses greater than 18 gestational
weeks in size, 2) conditions making them intolerant to anesthesia, 3) severe bleeding disorders, 4) acute
periodontitis of the upper abdomen with severe distension, or 5) a midline abdominal hernia.
Interventions AH versus LH [LH(a)].
LH(a) arm: Three 12-mm trocars were used, one placed infraumbilically and one placed in each lower
quadrant approx. 6-8 cm above the pubic rami, lateral to the inferior epigastric arteries. AHulka tenaculum
was used to manipulate the uterus. The bladder flap was developed by incising the vesicouterine fold of
peritoneum and dissecting the bladder below the cervix. The urethers were then identified and mobilized
using linear incisions in the medial leaf of the broad ligament, midway between the uterosacral ligaments
and infundibulopelvic vessels.
The Multifire EndoGIA disposable surgical stapler was used to staple-ligate and cut all uterine pedicles,
each consisting of the round ligament, fallopian tubes, and utero-ovarian ligament, were cut. If the
ovaries were to be removed, the stapler was instead placed outside the tube and ovary, encompassing the
infundibulopelvic ligament. The uterine arteries were next staple-ligated and cut bilaterally. If possible,
the stapling device was also used to ligate and cut the cardinal ligaments. Otherwise, stapling of uterine
pedicles ended and the anterior vaginal formix was enteredwith unipolar cautery, incising over amoistened
sponge distending the anterior vagina. The remainder of the hysterectomy was completed vaginally.
AH arm: modified Richardson technique.
Surgeon experience: not reported.
All received pre-operative antibiotic prophylaxis (cefazolin 2 g ) intravenously. If allergic to penicillin, 200
mg dose of doxycycline intravenously was used.
Follow up: 2 and 6 weeks post-operatively in the outpatient office.
Duration: not reported.
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Summitt 1998 (Continued)
Outcomes Operating time; blood loss; intraoperative and postoperative complications; hospital stay; febrile morbid-
ity; requirement for analgesia; recovery time; conversion to abdominal hysterectomy and costs.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Tsai 2003
Methods Randomisation: computer generated random number sequence.
Single centre study, parallel group design with no blinding.
Number of women randomised = 200, number analysed = 200. Not analysed on intention to treat basis
- two LAVHs converted to AH analysed as AH.
No power calculation for sample size reported.
Source of funding: not reported.
Participants 200 women with a mean age of 46.9 years (AH) and 46.7 years (LAVH), recruited from a university and
municipal hospital in Kaohsuing, Taiwan.
Inclusion criteria: good mobility of an enlarged uterus on bimanual pelvic examination.
Exclusion criteria: upper uterine margin higher than midpoint between symphisis pubis and umbilicus;
pre-existing cardiopulmonary dysfunction or poorly controlled systemic disease; cervical malignancy on
colposcopy; indication for conventional VH.
Interventions AH versus LH [LAVH].
AH technique not specified.
LAVH technique under GA as follows. Uterine manipulator applied and pneumoperitoneum established.
Two trocar puncture sites, 12 mm umbilically and 2 mm right lower quadrant. 2 mm minilaparoscope
allowed inspection and treatment of emdometriosis lesions or adhesions through umbilical port. Multifire
EndoGIA stapler resection of round and utero-ovarian ligaments (or bipolar forceps applied to round
ligaments if large myoma present). Vaginal phase included insertion of 10mm laparoscope after division
of the vesicouterine fold and peritoneal entry (the LETS technique). Then standard VH technique,
including clamping, transection and suture ligation of uterosacral, cardinal and uterine pedicles, followed
by peritoneal closure, then laparoscopic re-evaluation and lavage after haemostasis if necessary.
Antibiotic and thromboprophylaxis not specified.
Follow-up duration not specified.
Duration: August 1997 to March 1999.
Outcomes Operating time; complications; duration of hospital stay.
Notes
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Tsai 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Yuen 1998
Methods Randomisation: computer-generated sequence of random numbers.
Single centre study, parallel group design with no blinding.
Number of women randomised = 50, number analysed = 44. 4 declined the operation and 2 refused to
participate postoperatively.
No power calculation for sample size or analysis by intention to treat was reported.
Source of funding: Direct grant for research from the Chinese University of Hong Kong.
Participants 44 women with a median age of 44 (LH(a) group) and 43 (AH group), recruited from the Chinese
University of Hong Kong.
Inclusion criteria: no major medical diseases requiring hysterectomy for benign disorders.
Exclusion criteria: suitable for VH or a uterus larger than 16 weeks’ gravid size.
Interventions AH versus LH [LH(a)].
LH(a) arm: Performed with the use of three ports and bipolar desiccation for hemostasis. The laparoscopic
part of the operation stopped after securing the uterine arteries, and the remainder of the operation was
performed vaginally.
AH arm: Performed in the standard manner through a Pfannenstiel or lower midline incision.
Surgeon experience: not reported.
Follow up: until discharge from hospital.
Duration: January 1996 - June 1996 (6 months).
Outcomes Operation time; blood loss; postoperative stay and postoperative complications.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Characteristics of excluded studies [ordered by study ID]
Apoola 1998 Non-randomised comparison of VH and AH for women with moderately enlarged uterus. Women undergoing
VH had less blood-loss, a smaller haemoglobin drop and a shorter hospital stay.
Chapron 1999 Not a randomised controlled study. Study to assess hysterectomy techniques and the rate of total laparoscopic
hysterectomy (TLH).
Ellstrom 2003 Randomised trial of TLH versus AH (n=74), but did not measure any of our pre-specified outcome measures,
focussing on psychological well being. No differences were found.
Holub 2000 Randomised controlled trial (n=70) but compared two variants of LAVH (described in the study as LAVH and
VALH [vaginally assisted laparoscopic hysterectomy] respectively), rather than comparing LAVH with another
surgical approach. InLAVH, the round ligament, upper broad ligament, infundibulopelvic or uteroovarian ligament,
bladder pillars in preparation of the bladder flap were taken laparoscopically; the uterine vessels, cardinal-uterosacral
ligaments, anterior and posterior culdotomy and vaginal cuff closure were taken vaginally. In VALH, all steps were
performed laparoscopically, other than taking the uiterine vessels and vaginal cuff closure which were performed
vaginally. Operation time shorter for VALH (mean 81.33 versus 89.47 mins, p=0.01), with no other significant
differences in outcomes reported.
Howard 1993 Not a randomised controlled study. Allocated to study groups based on the attending physician scheduled for the
case. Intervention: laparoscopic hysterectomy (LH) versus abdominal hysterectomy (AH).
Møller 2001 Not a randomised controlled study, allocated to study groups by the attending gynecologist in a non-randomised
manner. Intervention: laparoscopic hysterectomy (LH) versus abdominal hysterectomy (AH).
Nezhat 1992 Not a randomised controlled study, alternatively assigned to study groups. Intervention: laparoscopic hysterectomy
(LH) versus abdominal hysterectomy (AH).
Oscarson 2003 Randomised trial comparing subtotal AH versus subtotal LH (n=48). The complication profile for subtotal hys-
terectomy is different to total hysterectomy. Inclusion of this trial and pooling for meta-analysis would introduce
undue clinical heterogeneity. No outcome differences found, other than operating time, which was longer for
subtotal LH.
Park 2003 Not a randomised controlled study. Historical comparison of LAVH and TLH.
Phipps 1993 Not a truly randomised controlled study, allocated to study groups according to the last digit of their hospital record
number by secretarial staff. Intervention: laparoscopic hysterectomy (LH) with bilateral salpingo-oophorectomy
(BSO) versus abdominal hysterectomy (AH) with BSO.
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Characteristics of studies awaiting assessment [ordered by study ID]
Cucinella 2000
Methods not detailed by review author
Participants
Interventions
Outcomes
Notes
Davies 1998
Methods not detailed by review author
Participants
Interventions
Outcomes
Notes
Hahlin 1994
Methods not detailed by review author
Participants
Interventions
Outcomes
Notes
Pabuccu 1996
Methods not detailed by review author
Participants
Interventions
Outcomes
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Pabuccu 1996 (Continued)
Notes
Petrucco 1999
Methods not detailed by review author
Participants
Interventions
Outcomes
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. VH vs AH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Operation time (mins) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Operation time (descriptive
data)
Other data No numeric data
3 Intraoperative complications
(dich)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bladder injury 3 239 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [0.31, 30.90]
3.2 Ureter injury 1 119 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.3 Urinary tract (bladder or
ureter) injury
3 239 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [0.31, 30.90]
3.4 Bowel injury 1 119 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.5 Vascular injury 1 119 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4 Intraoperative complications
(cont)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Estimated bloodloss (mls) 2 140 Mean Difference (IV, Fixed, 95% CI) -11.93 [-70.70,
46.84]
5 Intraoperative complications
(descriptive data)
Other data No numeric data
5.1 Estimated bloodloss Other data No numeric data
6 Short term outcomes (dich) 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Transfusion 4 295 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [0.46, 3.72]
6.2 Pelvic hematoma 3 235 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.28, 3.53]
6.3 Vaginal cuff infection 2 140 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
6.4 Wound/ abdominal wall
infection
2 155 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.18]
6.5 UTI 3 176 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.08, 4.61]
6.6 Chest infection 1 60 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.60]
6.7 Infection unspecified 4 295 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.21, 0.83]
6.8 Thrombo-embolism 1 119 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7 Short term outcomes (descriptive
data)
Other data No numeric data
7.1 Change in haemoglobin Other data No numeric data
8 Pain relief (descriptive data) Other data No numeric data
9 Recovery from surgery 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Length of hospital stay
(days)
3 235 Mean Difference (IV, Fixed, 95% CI) -0.95 [-1.24, -0.65]
9.2 Return to normal activities
(days)
3 176 Mean Difference (IV, Fixed, 95% CI) -9.47 [-12.57, -6.37]
10 Recovery from surgery
(descriptive data)
Other data No numeric data
11 Long term outcomes - negative
(dich)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Urinary dysfunction 1 80 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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12 Long term outcomes - positive
(dich)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Satisfaction 1 119 Odds Ratio (M-H, Fixed, 95% CI) 2.69 [0.50, 14.42]
Comparison 2. LH vs AH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Operation time (mins) 10 988 Mean Difference (IV, Fixed, 95% CI) 10.58 [7.39, 13.77]
1.1 LAVH versus AH 4 466 Mean Difference (IV, Fixed, 95% CI) -7.59 [-12.19, -2.98]
1.2 LH(a) versus AH 5 420 Mean Difference (IV, Fixed, 95% CI) 30.61 [25.58, 35.65]
1.3 TLH versus AH 1 102 Mean Difference (IV, Fixed, 95% CI) 16.30 [7.01, 25.59]
1.4 Non-categorisable LH
versus AH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Operation time (descriptive
data)
Other data No numeric data
3 Intra-operative complications
(dich)
12 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bladder injury 9 1810 Odds Ratio (M-H, Fixed, 95% CI) 2.04 [0.89, 4.67]
3.2 Ureter injury 4 1268 Odds Ratio (M-H, Fixed, 95% CI) 3.43 [0.83, 14.15]
3.3 Urinary tract (bladder or
ureter) injury
10 1912 Odds Ratio (M-H, Fixed, 95% CI) 2.61 [1.22, 5.60]
3.4 Bowel injury 2 1066 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.60]
3.5 Vascular injury 2 956 Odds Ratio (M-H, Fixed, 95% CI) 1.76 [0.52, 5.87]
3.6 Bleeding 4 1185 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.12, 1.31]
4 Short term outcomes (dich) 18 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Transfusion 13 2046 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.32]
4.2 Pelvic haematoma 6 563 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.46, 1.97]
4.3 Vaginal cuff infection 8 733 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.68, 3.25]
4.4 Wound/abdominal wall
infection
5 449 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.12, 0.85]
4.5 UTI 7 609 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.50, 1.92]
4.6 Chest infection 3 294 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.07, 1.35]
4.7 Infection unspecified 12 1879 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.49, 0.87]
4.8 Thrombo-embolism 2 1066 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.24, 5.13]
5 Short term outcomes (cont) 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Estimated blood loss (ml) 7 693 Mean Difference (IV, Fixed, 95% CI) -45.26 [-72.68, -
17.85]
5.2 Change in Hb 3 288 Mean Difference (IV, Fixed, 95% CI) -0.55 [-0.82, -0.28]
6 Short term outcomes (descriptive
data)
Other data No numeric data
6.1 Estimated blood loss (ml) Other data No numeric data
6.2 Change in Hb Other data No numeric data
7 Pain relief (descriptive data) Other data No numeric data
7.1 Pain scales Other data No numeric data
7.2 Postoperative analgesics Other data No numeric data
7.3 Recovery from pain (days) Other data No numeric data
8 Recovery from surgery 10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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8.1 Length of hospital stay
(days)
9 948 Mean Difference (IV, Fixed, 95% CI) -2.03 [-2.19, -1.88]
8.2 Return to normal activities
(days)
6 520 Mean Difference (IV, Fixed, 95% CI) -13.63 [-15.42, -
11.84]
9 Recovery from surgery
(descriptive data)
Other data No numeric data
9.1 Length of hospital stay
(days)
Other data No numeric data
9.2 Return to normal activities
(days)
Other data No numeric data
10 Long term outcomes - negative
(dich)
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Fistula 2 245 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.32, 29.96]
10.2 Urinary dysfunction 2 246 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.48, 1.84]
11 Long term outcomes - positive
(dich)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Satisfaction 1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.30]
12 Long term outcomes
(descriptive data)
Other data No numeric data
12.1 Satisfaction Other data No numeric data
13 Cost (descriptive data) Other data No numeric data
Comparison 3. LH sub-category analyses versus AH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bladder injury 10 1804 Odds Ratio (M-H, Fixed, 95% CI) 2.01 [0.88, 4.60]
1.1 LAVH versus AH 3 396 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.17]
1.2 LH(a) versus AH 3 300 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [0.37, 8.48]
1.3 TLH versus AH 2 42 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 2.59 [0.81, 8.32]
2 Ureter injury 5 1308 Odds Ratio (M-H, Fixed, 95% CI) 3.43 [0.83, 14.15]
2.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 LH(a) versus AH 1 100 Odds Ratio (M-H, Fixed, 95% CI) 6.12 [0.29, 130.87]
2.3 TLH versus AH 2 142 Odds Ratio (M-H, Fixed, 95% CI) 3.06 [0.12, 76.88]
2.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 2.82 [0.44, 18.03]
3 Urinary tract (bladder or ureter
injury)
8 1672 Odds Ratio (M-H, Fixed, 95% CI) 3.03 [1.34, 6.87]
3.1 LAVH versus AH 2 196 Odds Ratio (M-H, Fixed, 95% CI) 3.05 [0.12, 76.48]
3.2 LH(a) versus AH 3 308 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.64, 12.29]
3.3 TLH versus AH 1 102 Odds Ratio (M-H, Fixed, 95% CI) 3.06 [0.12, 76.88]
3.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [1.06, 9.28]
4 Bowel injury 2 1066 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.60]
4.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 LH(a) versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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4.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.60]
5 Vascular injury 2 956 Odds Ratio (M-H, Fixed, 95% CI) 1.76 [0.52, 5.87]
5.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 5.26 [0.24, 113.11]
5.2 LH(a) versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.4 Non-categorisable LH
versus AH
1 876 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.35, 5.08]
6 Bleeding 4 1185 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.12, 1.31]
6.1 LAVH versus AH 1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
6.2 LH(a) versus AH 2 193 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.34]
6.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6.4 Non-categorisable LH
versus AH
1 876 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [0.16, 14.51]
7 Transfusion 13 2046 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.54, 1.32]
7.1 LAVH versus AH 4 458 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.10, 1.40]
7.2 LH(a) versus AH 7 522 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.24, 0.97]
7.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 2.14 [0.95, 4.81]
8 Pelvic haematoma 6 563 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.46, 1.97]
8.1 LAVH versus AH 3 276 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.05, 2.10]
8.2 LH(a) versus AH 3 287 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.54, 2.75]
8.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
8.4 Non-categorisable LH
versus AH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9 Vaginal cuff infection 8 733 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.68, 3.25]
9.1 LAVH versus AH 3 396 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.37]
9.2 LH(a) versus AH 5 337 Odds Ratio (M-H, Fixed, 95% CI) 1.94 [0.75, 4.99]
9.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9.4 Non-categorisable LH
versus AH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10 Wound/abdominal wall
infection
5 449 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.12, 0.85]
10.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10.2 LH(a) versus AH 4 259 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.12, 1.03]
10.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10.4 Non-categorisable LH
versus AH
1 190 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.21]
11 UTI 7 609 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.50, 1.92]
11.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
11.2 LH(a) versus AH 5 339 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.55, 2.95]
11.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11.4 Non-categorisable LH
versus AH
1 190 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.18, 2.39]
12 Chest infection 3 294 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.07, 1.35]
12.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 LH(a) versus AH 2 104 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.10, 3.93]
12.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
12.4 Non-categorisable LH
versus AH
1 190 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.01]
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13 Infection unspecified 12 1879 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.49, 0.87]
13.1 LAVH versus AH 3 258 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.09, 0.89]
13.2 LH(a) versus AH 6 453 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.24, 0.75]
13.3 TLH versus AH 1 102 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.18]
13.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.63, 1.34]
14 Thromboembolism 2 1066 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.24, 5.13]
14.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14.2 LH(a) versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14.4 Non-categorisable LH
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.24, 5.13]
15 Estimated blood loss 7 693 Mean Difference (IV, Fixed, 95% CI) -45.26 [-72.68, -
17.85]
15.1 LAVH versus AH 3 396 Mean Difference (IV, Fixed, 95% CI) -33.08 [-68.27,
2.11]
15.2 LH(a) versus AH 4 297 Mean Difference (IV, Fixed, 95% CI) -64.08 [-107.82, -
20.35]
15.3 TLH versus AH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
15.4 Non-categorisable LH
versus AH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
16 Drop in haemoglobin 3 288 Mean Difference (IV, Fixed, 95% CI) -0.55 [-0.82, -0.28]
16.1 LAVH versus AH 1 116 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.83, -0.09]
16.2 LH(a) versus AH 2 172 Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.05, -0.27]
16.3 TLH versus AH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
16.4 Non-categorisable LH
versus AH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
17 Hospital stay (days) 9 948 Mean Difference (IV, Fixed, 95% CI) -2.03 [-2.19, -1.88]
17.1 LAVH versus AH 4 466 Mean Difference (IV, Fixed, 95% CI) -2.13 [-2.37, -1.90]
17.2 LH(a) versus AH 4 380 Mean Difference (IV, Fixed, 95% CI) -1.57 [-1.81, -1.34]
17.3 TLH versus AH 1 102 Mean Difference (IV, Fixed, 95% CI) -3.80 [-4.33, -3.27]
17.4 Non-categorisable LH
versus AH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
18 Return to normal activities
(days)
6 520 Mean Difference (IV, Fixed, 95% CI) -13.63 [-15.42, -
11.84]
18.1 LAVH versus AH 1 80 Mean Difference (IV, Fixed, 95% CI) -8.40 [-12.15, -4.65]
18.2 LH(a) versus AH 5 440 Mean Difference (IV, Fixed, 95% CI) -15.17 [-17.21, -
13.14]
18.3 TLH versus AH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
18.4 Non-categorisable LH
versus AH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
19 Fistula 2 245 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.32, 29.96]
19.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
19.2 LH(a) versus AH 1 143 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [0.12, 77.01]
19.3 TLH versus AH 1 102 Odds Ratio (M-H, Fixed, 95% CI) 3.06 [0.12, 76.88]
19.4 Non-categorisable LH
versus AH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
20 Urinary dysfunction 2 246 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.48, 1.84]
20.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
20.2 LH(a) versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
20.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
57Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
20.4 Non-categorisable LH
versus AH
1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.76]
21 Satisfaction 1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.30]
21.1 LAVH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21.2 LH(a) versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21.3 TLH versus AH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21.4 Non-categorisable LH
versus AH
1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.30]
Comparison 4. LH vs VH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Operation time (mins) 4 293 Mean Difference (IV, Fixed, 95% CI) 41.54 [33.67, 49.41]
1.1 LAVH versus VH 1 80 Mean Difference (IV, Fixed, 95% CI) 21.0 [8.05, 33.95]
1.2 LH(a) versus VH 3 213 Mean Difference (IV, Fixed, 95% CI) 53.58 [43.67, 63.49]
1.3 TLH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
1.4 Non-categorisable LH
versus VH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Operation time (mins)
(descriptive data)
Other data No numeric data
3 Intraoperative complications
(dich)
7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bladder injury 6 805 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.32, 2.56]
3.2 Ureter injury 1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
3.3 Urinary tract (bladder or
ureter) injury
6 805 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.36, 2.75]
3.4 Bowel injury 1 504 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.5 Vascular injury 4 685 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.48, 5.27]
3.6 Bleeding 1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
3.7 Unintended laparotomy 6 842 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.75, 3.21]
4 Short term outcomes(dich) 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Transfusion 5 801 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.80, 3.63]
4.2 Pelvic haematoma 2 160 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.06, 2.90]
4.3 Vaginal cuff infection 4 276 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.22, 4.39]
4.4 Abdominal wall infection 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
4.5 UTI 2 140 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.25]
4.6 Chest infection 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
4.7 Infection unspecified 5 780 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.26]
4.8 Thrombo-embolism 1 504 Odds Ratio (M-H, Fixed, 95% CI) 2.52 [0.12, 52.76]
5 Short term outcomes (cont) 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Estimated blood loss (mls) 3 196 Mean Difference (IV, Fixed, 95% CI) 9.72 [-50.21, 69.65]
5.2 Change in Hb 2 157 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.26, 0.56]
6 Short term outcomes (descriptive
data)
Other data No numeric data
6.3 Estimated blood loss (ml) Other data No numeric data
6.5 Change in Hb Other data No numeric data
7 Pain relief (descriptive data) Other data No numeric data
7.1 Pain scales Other data No numeric data
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7.2 Postoperative analgesics Other data No numeric data
8 Recovery from surgery 4 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Length of hospital stay
(days)
3 237 Mean Difference (IV, Random, 95% CI) 0.33 [-0.13, 0.79]
8.2 Return to normal activities
(days)
2 140 Mean Difference (IV, Random, 95% CI) -1.07 [-4.21, 2.06]
9 Recovery from surgery
(descriptive data)
Other data No numeric data
9.1 Length of hospital stay Other data No numeric data
9.2 Return to normal activities Other data No numeric data
10 Long term outcomes - negative 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Fistula 1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.67]
10.2 Urinary dysfunction 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
11 Cost (descriptive data) Other data No numeric data
Comparison 5. LH sub-category analyses versus VH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bladder injury 6 805 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.32, 2.56]
1.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
1.2 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.98 [0.30, 29.43]
1.3 TLH versus VH 1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.26]
1.4 Non-categorisable LH
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.18, 3.79]
2 Ureter injury 1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
2.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 LH(a) versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
3 Urinary tract (bladder or ureter)
injury
6 805 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.36, 2.75]
3.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
3.2 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.98 [0.30, 29.43]
3.3 TLH versus VH 1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.26]
3.4 Non-categorisable LH
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.23, 4.38]
4 Bowel injury 1 504 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 LH(a) versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5 Vascular injury 4 685 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.48, 5.27]
5.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.89 [0.11, 74.15]
5.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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5.4 Non-categorisable LH
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.39, 5.22]
6 Bleeding 1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
6.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 LH(a) versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
7 Unintended laparotomy 6 842 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.75, 3.21]
7.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 4.33 [0.46, 40.61]
7.2 LH(a) versus VH 3 213 Odds Ratio (M-H, Fixed, 95% CI) 6.11 [1.06, 35.21]
7.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7.4 Non-categorisable LH
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.26, 1.74]
8 Transfusion 5 801 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.80, 3.63]
8.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.04, 5.60]
8.2 LH(a) versus VH 3 217 Odds Ratio (M-H, Fixed, 95% CI) 2.49 [0.63, 9.86]
8.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
8.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [0.63, 4.79]
9 Pelvic haematoma 2 160 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.06, 2.90]
9.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
9.2 LH(a) versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.04, 5.60]
9.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10 Vaginal cuff infection 4 276 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.22, 4.39]
10.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.56]
10.2 LH(a) versus VH 3 196 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.16, 5.73]
10.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11 Wound/abdominal wall
infection
1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
11.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11.2 LH(a) versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
11.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
12 UTI 2 140 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.25]
12.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
12.2 LH(a) versus VH 1 60 Odds Ratio (M-H, Fixed, 95% CI) 3.10 [0.12, 79.23]
12.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
12.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
13 Chest infection 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
13.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
13.2 LH(a) versus VH 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
13.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
13.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14 Infection unspecified 5 780 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.26]
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14.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.56]
14.2 LH(a) versus VH 3 196 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.28, 3.51]
14.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.41, 1.25]
15 Thromboembolism 1 504 Odds Ratio (M-H, Fixed, 95% CI) 2.52 [0.12, 52.76]
15.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
15.2 LH(a) versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
15.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
15.4 Non-categorisable LH
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 2.52 [0.12, 52.76]
16 Estimated blood loss (mls) 3 196 Mean Difference (IV, Fixed, 95% CI) 9.72 [-50.21, 69.65]
16.1 LAVH versus VH 1 80 Mean Difference (IV, Fixed, 95% CI) 24.0 [-90.93,
138.93]
16.2 LH(a) versus VH 2 116 Mean Difference (IV, Fixed, 95% CI) 4.39 [-65.85, 74.63]
16.3 TLH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
16.4 Non-categorisable LH
versus VH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
17 Drop in haemoglobin 2 157 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.26, 0.56]
17.1 LAVH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
17.2 LH(a) versus VH 2 157 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.26, 0.56]
17.3 TLH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
17.4 Non-categorisable LH
versus VH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
18 Hospital stay (days) 3 237 Mean Difference (IV, Fixed, 95% CI) 0.33 [-0.13, 0.79]
18.1 LAVH versus VH 1 80 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.25, 0.85]
18.2 LH(a) versus VH 2 157 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.42, 1.22]
18.3 TLH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
18.4 Non-categorisable LH
versus VH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
19 Return to normal activities
(days)
2 140 Mean Difference (IV, Fixed, 95% CI) -1.07 [-4.21, 2.06]
19.1 LAVH versus VH 1 80 Mean Difference (IV, Fixed, 95% CI) -1.60 [-5.11, 1.91]
19.2 LH(a) versus VH 1 60 Mean Difference (IV, Fixed, 95% CI) 1.0 [-5.95, 7.95]
19.3 TLH versus VH 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
19.4 Non-categorisable LH
versus VH
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
20 Fistula 1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.67]
20.1 LAVH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
20.2 LH(a) versus VH 1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.67]
20.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
20.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21 Urinary dysfunction 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
21.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
21.2 LH(a) versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21.3 TLH versus VH 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
21.4 Non-categorisable LH
versus VH
0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 6. Comparisons of different types of LH - LH(a) versus LAVH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Operation time (mins) 1 101 Mean Difference (IV, Fixed, 95% CI) 25.30 [10.00, 40.60]
2 Intraoperative complications
(dich)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Bladder injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.06, 8.27]
2.2 Ureter injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) 3.03 [0.27, 34.52]
2.3 Urinary tract injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.83]
2.4 Bowel injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.5 Vascular injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.09, 24.27]
2.6 Conversion to laparotomy 1 104 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.06, 8.34]
3 Short term outcomes (dich) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Transfusion 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.13, 4.11]
3.2 Infection unspecified 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.83]
3.3 Vaginal cuff infection 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.45]
4 Estimated blood loss (descriptive
data)
Other data No numeric data
5 Long term outcomes (dich) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Dyspareunia 1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.64 [0.59, 11.72]
5.2 Orgasm (<1 of 3) 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.38, 1.86]
6 Recovery from surgery 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Hospital stay (days) 1 101 Mean Difference (IV, Fixed, 95% CI) Not estimable
6.2 Return to normal activities
(weeks)
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
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